Ordinary thiamine (vitamin B1) × Handgrip improvement in objectively weak adults

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Independent claimWhich population, route, and strength outcome does this table address?Required (selected handgrip question)	The current claim is a single comparative handgrip question about single-ingredient oral ordinary thiamine in adults with objectively reduced muscle strength. The source explicitly specifies a single independent claim, and no actual trial has been fixed. The original stored summary has no subclaims key.	This verifies preservation of the claim boundary. It does not mean that a directly eligible trial or effect has been verified.	Current independent claim, adults with objectively reduced muscle strength, oral ordinary thiamine, comparator, and handgrip boundary	Verify comparative handgrip data that meet this boundary, and assess other endpoints and formulations as separate questions.
2	Unverified	Full text not readStored summary read	N02 · Ingredient, salt, and productHave the ordinary-thiamine salt and single-ingredient product in the target trial been verified?Required (selected handgrip question)	The question concerns single-ingredient ordinary thiamine, but no eligible study has been selected, so the actual salt and product are unverified. The actual_salt field in the assessment question's identity is null. It was not filled using the mixture of CMT hydrochloride and derivative exposures or the separate 100 mg product in S15. S05 S06 S11 S15	The eligible product and actual chemical form cannot be identified within the current retained scope.	Base/hydrochloride/nitrate, manufacturer, ingredients/excipients, and free-thiamine-equivalent amount of the product in an eligible original report	Compare product and ingredient records from an eligible trial, and extract derivative/combination exposures separately.
3	Partly verified	Full text not readStored summary read	N03 · Route and physical dosage formHave the question's oral route and the actual tablet/capsule form been distinguished?Required (selected handgrip question)	The claim's route is oral, and injections are not allowed. The physical dosage form of an actually eligible product is unverified. The intramuscular 100 mg, 2 times per week cases in S09 and the tablets in S15 were not used as the oral product in the target handgrip trial. S09 S15	The route boundary is clear, but the actual eligible product and physical dosage form have not been verified.	Oral route, physical dosage form, and manufacturing/batch data for an eligible comparison	Verify administration and physical dosage form in the original trial, and link injection and derivative evidence separately.
4	Unverified	Full text not readStored summary read	N04 · Nominal and actual doseHave the dose and adherence in the target handgrip trial been verified?Required (selected handgrip question)	The actual_dose and verified_values.dose fields for an eligible handgrip comparison are null. Wilkinson's 10 mg/day and TARIF's 600–1800 mg/day are historical exposures in different populations/outcomes. No dose conversion, calculation, or dosing suggestion was made in this work. S01 S03	Actual dose, schedule, adherence, and handgrip outcomes by dose for the target comparison are unverified.	Nominal dose, dosing schedule, active amount, actual adherence/exposure, and concomitant supplementation by eligible group	Link dosing/adherence records for an eligible product to outcome denominators, and assess direct dose comparisons separately.
5	Unverified	Full text not readStored summary read	N05 · Duration and principal time pointHave the eligible treatment duration and handgrip measurement time point been verified?Required (selected handgrip question)	The treatment duration and principal handgrip time point of a selected eligible trial are null. Wilkinson's 3 months, TARIF's 4-week periods and washout, and allithiamine's 5 days were not combined as target efficacy over the same period. S01 S03 S12	The appropriate duration, principal time point, and sustained effect for the target handgrip comparison have not yet been verified.	Eligible treatment duration, principal handgrip time point, follow-up after discontinuation, and measurements by visit	Verify visit, treatment, and discontinuation times in an eligible comparison, and assess maintenance effects using separate data.
6	Unverified	Full text not readStored summary read	N06 · Population and reduced strengthIs there an actual enrollment cutoff for objectively reduced muscle strength?Required (selected handgrip question)	The target is adults with objectively reduced muscle strength, but actual_weakness_cutpoint is null. Older adults with low TPP in TF01, IBD patients with fatigue in TF02, and healthy students do not automatically meet that definition. S01 S03 S12	The eligible reduced-strength cutoff, baseline distribution, and selected subgroup are unverified.	Adult inclusion/exclusion, definition of objectively reduced handgrip, cutoff, baseline distribution, and verified subgroup	Obtain enrollment criteria, individual/subgroup baseline handgrip, and prespecified definitions before comparing population eligibility.
7	Unverified	Full text not readStored summary read	N07 · Nutritional status and deficiencyCan deficiency correction be separated from the effect of general additional supplementation?Required (selected handgrip question)	Thiamine status in an actually eligible population is null. Selection for low erythrocyte TPP and objectively reduced muscle strength are different criteria, and deficiency correction or refeeding management does not replace evidence of efficacy for general handgrip supplementation. S01 S16 S17	Nutritional status and effects by deficient/nondeficient status in the target comparison have not been verified.	Thiamine status, deficiency definition, handgrip outcomes by status, and deficiency-treatment context in an eligible population	Compare status definitions, treatment context, and direct handgrip comparisons by status separately.
8	Unverified	Full text not readStored summary read	N08 · Comparison and background careHave the actual comparator and balance of concomitant treatments been verified?Required (selected handgrip question)	The question's comparators are placebo, no added thiamine, or usual care with all other treatments matched. The actually eligible comparator is null. Mixed CMT formulations/other treatments and healthy-participant biomarker comparisons are not matched untreated long-term handgrip comparators. S05 S06 S07	Group-specific concomitant-treatment and exposure data needed to distinguish the eligible comparison and the selected thiamine's contribution are unverified.	Eligible placebo/no added thiamine/matched usual care, concomitant treatments, changes/rescue treatment, and adherence	Link background care and changes by group to the analysis of the actual effect of interest.
9	Unverified	Full text not readStored summary read	N09 · Handgrip measurementIs there an actual target measurement specifying hand, device, units, and repeated-measurement rules?Required (selected handgrip question)	For the target handgrip outcome, actual_device, actual_hand, actual_units, and the principal time point are null. Dominant-hand Preston measurement in TF01 is adjacent-trial information and does not automatically establish repeated-measurement rules or the target protocol. S01	Actual measurement, aggregation, group-specific assessment conditions, and units for the target handgrip outcome are unverified.	Eligible handgrip device/calibration, hand, posture, repetition/aggregation rules, units, assessor masking, and principal time point	Extract eligible testing procedures and implementation/assessment by group together with the original handgrip results.
10	Partly verified	Full text not readStored summary read	N10 · Endpoint hierarchyHave the page's handgrip question and the original trial's primary endpoint been distinguished?Required (selected handgrip question)	The question-level endpoint is fixed as handgrip. No directly eligible trial has been selected, and the actual prespecified endpoint hierarchy is unverified. TARIF remains in the context of primary fatigue and an excerpt concerning secondary handgrip. S03 S18	The page's endpoint is clear, but comparison of eligible prespecified hierarchy with reporting is incomplete.	Handgrip endpoint, principal time point/analysis hierarchy in eligible registration/planning records, and actual reporting	Compare registration, protocol, and analysis plan with actual handgrip reporting.
11	Partly verified	Full text not readStored summary read	N11 · TF01 enrollmentAre the 76 older adults with low TPP an objectively weak population?Required (selected handgrip question)	Wilkinson is a placebo-controlled study of 10 mg/day for 3 months in 76 older adults. The entry criterion was erythrocyte TPP <140 nmol/L, not an objective reduced-strength cutoff. It was therefore not selected as directly eligible for the current target efficacy question. S01 S02	The trial exists, but a direct comparison in an objectively weak population or prespecified stratum has not been verified.	Wilkinson enrollment criteria, TPP strata, baseline low-handgrip cutoff/prespecified subgroup	Verify original enrollment, baseline handgrip, and prespecified comparisons by stratum to prepare material for reassessing eligibility.
12	Partly verified	Full text not readStored summary read	N12 · TF01 testing and timingHas the scope of dominant-hand Preston grip measurement and 3 months of exposure been preserved?Required (selected handgrip question)	The retained TF01 record describes dominant-hand grip with a Preston dynamometer and oral 10 mg/day for 3 months. S01 was an HTML reproduction of the original report on a 3rd-party host at that time, with recorded layout errors in text extraction from the two-column article. The original clinical full text was not reread in this work. S01	Testing and duration information is retained, but the quantitative contrast, applicability of units/repetition procedures to the target, and current comparison with the original text are unverified.	S01 testing, units/repetitions, time points, original results tables, and quantitative handgrip contrast	Verify testing procedures and analysis values in the original Methods/Results/tables, and link them to the same outcome.
13	Partly verified	Full text not readStored summary read	N13 · TF01 allocation and maskingDoes a randomized/double-blind label establish actual implementation?Required (selected handgrip question)	TF01 is recorded as a randomized double-blind placebo-controlled parallel trial stratified by pretreatment TPP status. The current input is not independent verification of actual concealment, masking success, or adherence by group. S01	The design is reported, but information is insufficient to establish actual implementation/adherence or outcome-specific bias.	S01 allocation/concealment, who was masked/masking success, baseline balance, actual adherence, and analysis handling	Compare the original methods with baseline, implementation, and analysis information for the handgrip outcome of interest.
14	Partly verified	Full text not readStored summary read	N14 · TF01 denominatorsAre 38 versus 38 and completion by all being turned into a handgrip analysis denominator?Required (selected handgrip question)	The retained TF01 evidence records 76 participants, 38 thiamine/38 placebo, and completion by all. These were not automatically used as the analysis count for the target eligible population or the number of handgrip observations at every time point. The eligible handgrip effect/CI are null. S01	The verification levels of participation/completion information and handgrip-specific analysis denominators/intervals differ.	Allocation/completion, handgrip measurement and analysis denominators, missingness, and variance/intervals	Link measurement/analysis counts at each time point in the original handgrip tables with missing-data handling and variance definitions.
15	Partly verified	Full text not readStored summary read	N15 · TF01 nonsignificance and estimationIs handgrip nonsignificance being read as an effect of 0 or equivalence?Required (selected handgrip question)	The retained Wilkinson record states that handgrip did not change significantly, but provides no quantitative treatment contrast, CI, or exact P. The historical extraction stating that Table 3 lacks a handgrip-change contrast is preserved, and no conclusion of no effect or equivalence was made. S01	There is a statement of nonsignificance, but magnitude, precision, and exclusion of a meaningful benefit have not been verified.	Original handgrip treatment contrast, variance, CI, exact P, and analysis population/model	If the original between-group handgrip estimate/interval and analysis definition are acquired, compare them separately from clinical importance.
16	Partly verified	Full text not readStored summary read	N16 · Funding and provisionIs funding from indirect trials being borrowed as independent efficacy replication?Required (selected handgrip question)	TF01 funding was from Canterbury Medical Research Foundation and Sanitarium Health Food Company; product provision was not reported. TF02 records Danish foundations, and TF03 records Russian foundation/State Task support; product provision is unverified. These were not borrowed to assign the independence axis for directly eligible evidence. S01 S04 S05	Funding is reported, but complete product/author conflict-of-interest information and eligible independent replication have not been verified.	TF01/TF02/TF03 funding, product provision, author declarations/patents, and family relationships	Compare original Funding/COI, product provision, and family relationships by outcome.
17	Partly verified	Full text not readStored summary read	N17 · TF02 population and endpointIs a handgrip excerpt from an IBD-fatigue crossover trial the target result?Required (selected handgrip question)	TARIF is a 40-participant trial in quiescent IBD with severe chronic fatigue, with fatigue as the primary endpoint. An objectively weak enrollment population or prespecified low-strength treatment stratum was not verified, and handgrip nonsignificance is in the context of an indexed excerpt. Existing fatigue verdict 3086 was not changed. S03 S04	Related human research exists, but population eligibility and handgrip values/denominators have not been verified.	TARIF baseline reduced-strength enrollment/strata, handgrip analysis results, and fatigue/handgrip hierarchy	Compare original handgrip subgroups, results, and denominators with the prespecified plan to reassess eligibility.
18	Partly verified	Full text not readStored summary read	N18 · TF02 crossover and analysisAre the 40 participants across two periods being counted as independent participants or a between-group handgrip effect?Required (selected handgrip question)	The retained TARIF record describes a 40-participant crossover trial comparing 600–1800 mg/day in 4-week periods separated by a 4-week washout. Handgrip analysis denominators, quantitative effect/CI, paired data, and carryover handling were not verified. Participants were not combined as independent people/trials across the two periods. S03 S04	The crossover schedule is available, but the target handgrip estimand, denominator, model, and precision are unverified.	4-week treatment, 4-week washout, sequence/period, paired data, handgrip analysis counts, and carryover/model	Verify sequence, period, paired variance, handling of carryover, and actual denominators in the original crossover handgrip analysis.
19	Partly verified	Full text not readStored summary read	N19 · TF02 registrationHave the NCT identifier and actual reading of the plan/amendment history been distinguished?Required (selected handgrip question)	NCT03634735 is an identifier verified in the original report. At that time, an official page shell, web API error, and native API DNS failure prevented verification of the content; prospective registration timing was also not independently verified. No new registration lookup was performed in this work. S18	The number is available, but comparison of the actual plan, handgrip hierarchy, amendments, and prospective timing is unverified.	Structured content of NCT03634735, original registration timing, handgrip hierarchy/analysis, and amendment history	In an authorized update, compare the official registration/history with the handgrip plan in the original report.
20	Partly verified	Full text not readStored summary read	N20 · TF02 subsequent reportsIs the supplied 3086 extraction being read as new full-text reading or independent replication?Required (selected handgrip question)	S19 is a lead from the previously supplied 3086 snapshot concerning the TARIF metabolic analysis and PMID34592862 maintenance follow-up. It is a historical record reusing the same family and oral HCl identity context, not new original full-text reading, fatigue reassessment, or handgrip replication in this work. S19	A supplied record exists, but report-specific handgrip results/eligibility and current comparison with original texts are unverified.	Original identities of subsequent metabolic/maintenance reports, common family/population, and handgrip endpoint/access	Verify the original identity, cohort, and handgrip data in each subsequent report, and link it to the same family.
21	Partly verified	Full text not readStored summary read	N21 · TF03 composition and denominatorsAre the 15, 14, 5, and 2 participants counted as the same trial of a pure oral preparation in adults?Required (selected handgrip question)	The retained CMT supplementary material records 14 adults among 15 participants, 5 adult hydrochloride rows, and 2 participants identified in the long-term hydrochloride handgrip figure. A patient aged 16, derivatives, and other treatments are mixed in. These denominators were not used as a single randomized oral-treatment comparison in adults or as a total of independent participants. S05 S06 S07	The mixed composition is recorded, but there is no matched control or between-group handgrip estimate for a pure oral preparation in adults.	Age, formulation, other treatments, and participants/denominators for handgrip follow-up in each row of the CMT supplementary material	Link age, formulation, and follow-up results from the original Table S1/figures to individual rows.
22	Partly verified	Full text not readStored summary read	N22 · TF03 handgrip figureWere HCl in patients 1 and 3 distinguished from sulbutiamine in patient 2?Required (selected handgrip question)	In the retained Figure 1 description, patients 1 and 3 received thiamine HCl, and patient 2 received sulbutiamine. The Russian/English reports and supplementary material belong to the same family. Before-and-after handgrip observations were not converted into a causal between-group effect, and derivatives were not pooled with ordinary thiamine. S05 S06 S07	Patients/formulations were distinguished, but a matched comparator and quantitative between-group handgrip effect remain unverified.	Patient-specific formulations, durations, handgrip follow-up, concomitant treatments/controls, and original measurements in Figure 1	Compare each patient's handgrip follow-up with actual exposure/concomitant treatment, and obtain comparison data under the same conditions separately.
23	Met	Full text not readStored summary read	N23 · TF03 biomarkers and controlsIs a healthy-person biomarker comparison an untreated handgrip control?Required (selected handgrip question)	The currently retained record does not treat the healthy metabolic comparison group as an untreated long-term handgrip control. Figure S2 contains biomarker data, not a handgrip treatment contrast. The visual review of 3 supplementary PDF pages for S06 is a historical access record. S05 S06	This verifies the boundary preventing repurposing of other outcomes/controls. It does not establish acquisition of an eligible handgrip comparison.	Actual comparators, tests, and time points for the biomarker comparison/Figure S2 and long-term handgrip observations	Check the original materials for an actual control with the same handgrip measurement, time point, and exposure.
24	Partly verified	Full text not readStored summary read	N24 · TF03 correctionWere the existence of a correction and verification of its actual full text distinguished?Required (selected handgrip question)	S08 records the existence of a formal correction, but its full text was inaccessible at the time. Distinguish the original publisher's page-range correction of 1–22→1161–1182 from the search excerpt about gray shading in Table3. The excerpt was not promoted to verified correction text, and no new correction lookup was performed in this work. S08	The existence/bibliographic record of a correction and its actual impact on clinical text have different levels of verification.	Original/corrected versions, page changes, scope of text/table corrections, and effects on attribution of handgrip observations	During a permitted update, compare the complete correction with the original table and review linked observations/statuses.
25	Met	Full text not readStored summary read	N25 · TF04 injection casesAre the two DM1 cases being read as an oral-treatment handgrip comparison?Required (selected handgrip question)	The two DM1 cases in S09 involved intramuscular thiamine 100 mg 2 times per week, not a controlled oral-treatment dynamometer trial. The historical full_text_HTML access record was not reused as a claim of current full-text reading. S09	This is a retained classification verifying differences in route/design, not verification of target efficacy.	Actual route, 100 mg 2 times per week, symptoms/measurements, and presence or absence of a control in the DM1 cases	Preserve the exposures/measurements in the original cases and review the target oral-treatment handgrip comparison using separate materials.
26	Partly verified	Full text not readStored summary read	N26 · TF05 general healthIs well-being in healthy older women being transferred to a handgrip effect in people with low muscle strength?Required (selected handgrip question)	The retained S10 record concerns 80 healthy older women, 10 mg/day, and 6 weeks of double-blind treatment following a 4-week baseline. Selection for low muscle strength and a separate objective muscle-strength contrast were not verified, and well-being results were not borrowed as a handgrip benefit. S10	An adjacent trial exists, but the target low-strength population/handgrip outcome remains unverified.	Smidt's baseline definition of low muscle strength, handgrip results, health/well-being endpoints, and denominators	If original eligibility criteria/handgrip measurements are available, compare them with the conditions of the same question.
27	Met	Full text not readStored summary read	N27 · TF06 TTFDAre the TTFD title and landing page being read as numerical evidence for ordinary thiamine?Required (selected handgrip question)	S11 identifies a different molecule from the title/landing page of an original TTFD article. The full text was not extracted, and no numerical results are claimed. It was not pooled as direct evidence for the ordinary-thiamine question. S11	This verifies the molecular/access boundary, not original effect estimates or target efficacy.	Original molecular identity, title/material type, and level of access to actual population/measurement results	Link the derivative to a separate question and verify direct results for ordinary thiamine separately.
28	Met	Full text not readStored summary read	N28 · TF07 allithiamineIs an isokinetic P>0.05 in healthy participants being read as no handgrip effect?Required (selected handgrip question)	Doyle concerns a placebo crossover study of allithiamine 1 g/day for 5 days in 15 healthy students, with isokinetic muscle performance measured using Biodex System2. P>0.05 does not establish no effect or equivalence for ordinary thiamine, adults with low muscle strength, and handgrip. S12	This verifies the boundary for a different molecule/population/endpoint. The target effect size/interval remains unverified.	Allithiamine, 15 healthy students, 5 days/1 g, Biodex isokinetic results, and original intervals	Attribute the original result to its derivative/isokinetic question and review the handgrip comparison separately.
29	Partly verified	Full text not readStored summary read	N29 · TF08 functional recoveryWere FIM recovery, actual handgrip, and an oral-treatment comparison distinguished?Required (selected handgrip question)	S13 contains FIM functional-limitation/recovery data. Detailed methods and route/comparator could not be verified from the historical indexed abstract excerpt and full-text 402 failure record. FIM was not converted into a separate handgrip contrast. S13	Adjacent functional data exist, but the identity of the target oral treatment/handgrip outcome/comparator remains unverified.	FIM results, actual route/comparator, separate handgrip testing, and access to original methods	If original methods/handgrip data are acquired, compare the actual route, control, and endpoint for correspondence.
30	Met	Full text not readStored summary read	N30 · Other diseases and combinationsDo PBC fatigue and B-vitamin/magnesium results replicate a single-ingredient handgrip effect?Required (selected handgrip question)	S20 is a PBC fatigue trial and is not counted as a refutation or replication for handgrip. S21 is a lead for an IBD fatigue trial of combined B1/B6/B12+magnesium, from which the handgrip efficacy of B1 alone cannot be isolated. The unverified DOI in the 2026 record and the status of the supplied composition snapshot were preserved. S20 S21	This verifies the boundary for another disease, a combination, and fatigue. It does not establish acquisition of a target handgrip comparison.	The disease/endpoint in S20 and the combined ingredients/fatigue question and original access in S21	Separate actual results by question and review the single-ingredient handgrip comparison using separate materials.
31	Met	Full text not readStored summary read	N31 · Dietary associationIs a micronutrient association in Korean adults being recast as supplementation efficacy?Required (selected handgrip question)	S23 contains dietary observational data on micronutrients and handgrip in Korean adults. It is not randomized assignment to single-ingredient oral supplementation; dietary intake was not converted into a supplementation dose, and the association was not converted into causal efficacy. S23	This verifies the association/intervention boundary, not direct handgrip efficacy or a need for supplementation.	Dietary observational design, direction of the exposure/handgrip association, and presence or absence of an actual randomized supplementation comparison	Link the dietary association to its original direction and verify a single-ingredient supplementation handgrip comparison separately.
32	Met	Full text not readStored summary read	N32 · Reports and familiesHow should 23 sources, 11 families, and 0 directly eligible comparisons be interpreted?Required (selected handgrip question)	The 23 current sources/citations entries are a provenance list mixing clinical reports, supplements/corrections, registrations, safety sources, reviews, and bibliographic leads. The records of 11 structural families and 0 directly eligible comparisons are preserved without interpreting them as an absence of all human research. CMT translations/supplements/corrections and TARIF follow-up reports belong to their respective existing families; the TF01 related report from 2000 remains only an unverified lead for possibly shared recruitment of 222 people. S01 S02 S03 S04 S05 S06 S07 S08 S18 S19 S22	This verifies the retained family/duplication policy. Total unique study/participant counts from a comprehensive search have not been verified.	Links from report to study/case family to endpoint/time point; provisionally related reports; duplication/unique counts	Verify recruitment/registration/population/result links for each report and preserve relationships identified as the same or unknown.
33	Unverified	Full text not readStored summary read	N33 · Target effect and analysisIs an unverified effect being filled in using within-group changes or baseline handgrip?Required (selected handgrip question)	For eligible handgrip, primary_effect, primary_CI, and primary_p are null, and the effect direction is unknown. E0/E+ was not assigned from within-group changes, baseline handgrip, or adjacent nonsignificant findings, and no new clinical calculations were performed in this work. S01 S03 S05	The eligible effect of interest, original analysis population/model, and estimate/interval remain unverified.	Eligible between-group handgrip estimand; ITT/PP/adjustment; original effect/CI/exact P; denominators	Verify the effect of interest, population, and between-group estimate/interval together in an eligible original analysis.
34	Unverified	Full text not readStored summary read	N34 · Precision and meaningDoes objective handgrip guarantee a benefit in daily function or clinical events?Required (selected handgrip question)	An eligible between-group CI and MCID have not been verified. Objective measurement alone does not make handgrip H or P, and force measurement differs from improvement in daily function. The existing axes remain unscored; no arbitrary P/S, C1/C0/CX, or participant-count/duration criteria were assigned.	Without an effect interval, its importance, and the meaning of the actual measurement, a meaningful benefit can neither be established nor ruled out.	Eligible handgrip interval, justified important difference, meaning of the test, and separate daily-function outcomes	Verify the original interval and a valid criterion for handgrip importance; review function/events separately using direct data.
35	Unverified	Full text not readStored summary read	N35 · Plans and selective reportingIs selective reporting being established merely because an eligible registration/plan is unavailable?Required (selected handgrip question)	No directly eligible handgrip trial could be selected, so comparison with its registration/plan remains unverified. The unverified TF01 registration, the distinction between TF03 ethics approval and trial registration, and TARIF history-access limitations were preserved. These are not interpreted as confirmed selective reporting. S01 S05 S18	Materials needed to verify an eligible comparison of the prespecified plan with the report and the original reasons for changes remain unverified.	Eligible original registration/protocol/analysis plan, endpoints/time points, reasons for changes, and corrected versions	After comparing an actual eligible plan with the handgrip report, record the scope of changes/selection.
36	Partly verified	Full text not readStored summary read	N36 · Harms of an oral productDoes a separate 100 mg SmPC provide the safety denominator for the target exposure?Required (selected handgrip question)	S15 records nausea, vomiting, diarrhea, abdominal pain, and hypersensitivity with unknown frequency for a specific oral thiamine hydrochloride 100 mg product. Allergy to product excipients is also separate. Harm denominators/frequencies in a target eligible trial and doses safe for long-term use in renal/hepatic impairment remain unverified. S15	A separate product provides harm context, but incidence and long-term safety for the target population/actual exposure have not been verified.	Product-specific adverse reactions/frequencies in S15; eligible actual exposure/duration and population; collection, discontinuations, and denominators	Link adverse-event collection, group-specific denominators/durations, and discontinuations for an eligible exposure to the product identity.
37	Partly verified	Full text not readStored summary read	N37 · Safety by route and special populationAre injection-related hypersensitivity and product-specific pregnancy/pediatric restrictions being generalized?Required (selected handgrip question)	Reports of severe hypersensitivity were mainly observed with injections, and their risk rate is not applied to oral preparations. The S15 product is not intended for pregnancy/lactation and is not recommended below 3 years of age, but these restrictions are not generalized to contraindications to all nutritional thiamine intake. The adult handgrip question is not extended to children/pregnancy. S15	Route/product-specific cautions exist, but these materials do not verify population-specific safety in the target trial.	Route of hypersensitivity reactions, product-specific pregnancy/lactation and age recommendations, and applicability to populations	Link safety materials for the relevant product/route/population separately from the efficacy question.
38	Partly verified	Full text not readStored summary read	N38 · Interactions and medical managementDo dialysis, malabsorption, and refeeding management establish the benefit of general handgrip supplementation?Required (selected handgrip question)	Furosemide may affect thiamine status, and fluorouracil requires separate review. Requirements in dialysis/malabsorption and medical management of alcohol-related deficiency/refeeding do not establish general high-dose oral handgrip efficacy or a safety upper limit. Combined NICE management is not used as evidence for single-ingredient efficacy. S14 S16 S17	Medical/drug caution contexts exist, but direct efficacy, the full range of interactions, and safety limits for the target exposure remain unverified.	Drug interactions, requirements in dialysis/malabsorption, and actual medical management of alcohol-related deficiency/refeeding	Review relevant drugs/medical situations by product/population, separately from direct target handgrip data.
39	Partly verified	Full text not readStored summary read	N39 · UL and safety limitsAre the absence of an established UL and water solubility being read as unlimited safety?Required (selected handgrip question)	Retained S16 and safety_detail state that no UL was established because toxicity data were insufficient. Water solubility and urinary excretion do not guarantee unlimited safety. The target dose safe for long-term use in renal/hepatic impairment also remains unverified, and study doses are not individual recommendations. S14 S16	The reason for the absence of a UL is recorded, but this does not verify target high-dose/long-term safety.	Reason no UL was established, actual toxicity data, safety by population/dose/duration, and harm denominators	If toxicity/harm data for a population/exposure are added, compare them with the original product and denominator/duration.
40	Not applicable	Full text not readStored summary read	N40 · Separate expanded questionsAre data on optimal dose, maintenance, subgroups, and falls/mortality being imposed as mandatory for this table?Supplementary (required if a separate expanded claim is made)	The current standalone question concerns comparative handgrip efficacy, not optimal dose, persistence after discontinuation, or prevention of falls/mortality. Extension studies are not imposed as requirements for this narrow question. Unverified actual target dose, duration/principal time point, and direct handgrip effect remain recorded in earlier rows.	Requiring expanded questions is not applicable. This does not replace gaps in the original handgrip exposure/population/outcome or verify effects for expanded questions.	Identity and direct evidence for the original handgrip question and separate dose, maintenance, function, and event extensions	If an expanded question is raised separately, review direct dose, follow-up, subgroup, function, and event results separately.
41	Partly verified	Full text not readStored summary read	N41 · Scope of searches and absence claimsIs unverified eligibility in the recorded search being declared an absence of human research?Required (selected handgrip question)	The original evidence cutoff date is 2026-09-16, and the original reader-facing answer limits its statement to no directly eligible controlled result being verified in the recorded search. The S22 review serves only as a literature map/indexed excerpt and is not used for decisive numbers or scoring. No new search, correction/retraction lookup, or reading of old search/extraction files was performed in this work. S22	A retained search scope exists, but an up-to-date exhaustive/unpublished-study/correction check and actual comparison with old separate files were not performed.	The 2026-09-16 search/cutoff date, actual inputs/failures, and scope for unpublished studies, registrations, corrections, and retractions	In a separately permitted update, record actual search/registration/correction results and the scope of failures/unverified information.
42	Met	Full text not readStored summary read	N42 · Original assessment and document qualityAre the original ?/null, document A, and calculator exception being read as new evidence?Required (selected handgrip question)	The original grade is ?, the score is null, the safety label is Caution, and the downstream evidence axes remain unscored. Preserve human_study_exists=true alongside unverified direct eligibility. The calculator's eligibility gap/invalid raw suggestion is an unadopted historical record; the calculator was not run in this work. Document A/ChatGPT self-review is not independent clinical review or efficacy certification.	This verifies the distinction between the roles of original values and document/calculation metadata. It is not a new clinical judgment or score.	Original grade/score, unscored axes, eligibility exception, document evaluation, and reviewer identity	Link new direct evidence or a schema change to a separate event/version and judgment.
43	Met	Full text not readStored summary read	N43 · Reading and original bytesAre summary reading and historical full-text access being shown as the same verification?Required (selected handgrip question)	What was read in this work was the KO/evidence/bibliography/historical-access content of the retained summaries. Distinguish historical records of the reproduced HTML for S01, supplementary PDF for S06, full text for S09, and official safety full texts from the current non-reading of all external materials. snapshot_policy covers limited extraction/bibliography, not redistributed copies of original full texts. Link summary reading through exact locations/values and retained-summary SHAs. S01 S06 S09 S14 S15 S16 S18 S19	This verifies exact retained-summary linkage. It is not current clinical full-text reading or verification of external original bytes.	Physical type, historical access level/location, current non-reading, and retained-summary pointer/literal/SHA for each material	If new materials are permitted, link actual acquisition/reading and original bytes/versions to the relevant rows/materials.
44	Met	Full text not readStored summary read	N44 · Identity, dates, and updatesIs historical deployment metadata being read as publication in this work?Required (selected handgrip question)	Preserve current ID3117, the original URL, the 2026-09-16 cutoff/publication date, historical server_deployed metadata, and revision_history. The review date of the retained sheet is 2026-10-05, and no public deployment was performed in that review. New eligible comparisons, original methods/strata, plans, or corrections/errors trigger separate review of rows/conditions/materials.	This verifies preservation of identity/date/update links. It is not publication in this work or verification of the latest corrections.	Current ID/URL, evidence/review dates, original revision/deployment metadata, and links between update events/criteria versions	If new materials/corrections are permitted, preserve the full original text and review it with links to events, versions, and change decisions.

No items match your search or filter.

44 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-05
Original evidence cut-off: 2026-09-16
Scope actually checked: Stored Korean and English manuscripts and case-specific criteria and application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of an up-to-date clinical literature search.
Population: Adults with objectively verified reduced muscle strength; actual cutoff and thiamine status unverified
Ingredient, formulation and route: Single-ingredient oral preparation; thiamine base/hydrochloride/nitrate kept separate, selected salt unverified
Dose: Eligible-study dose unverified
Comparator: Placebo, no added thiamine, or usual care with all other treatments matched
Measured outcome: A single handgrip endpoint; hand, device, repeated-measurement rules, units, and principal time point unverified
Duration: Eligible-study treatment duration unverified
Questions outside this scope: Do not combine fatigue, muscle mass, walking, neurological symptoms/deficiency correction, injections/derivatives/combinations, dietary associations, or separate functional/event outcomes into a direct handgrip effect.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Wilkinson et al. 1997. The response to treatment of subclinical thiamine deficiency in the elderly

Source

Material type: Adjacent RCT in older adults with low TPP
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Full original text reproduced by a third-party host; primary publisher DOI/ScienceDirect access failed. Two-column text extraction has layout artifacts. Grip test, design and results prose distinguishable; no quantitative grip-change contrast in Table 3. · Although 10 mg/day for 3 months was compared with placebo, no quantitative handgrip treatment contrast, CI, or exact P value was reported. Nonsignificance was not treated as equivalence or no effect. · Denominator: 76 participants; 38 thiamine, 38 placebo; all completed · Role: The closest controlled trial, but excluded from target efficacy scoring because the population did not match objectively weak adults
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Original-article HTML reproduced by a 3rd-party host Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S02 · Wilkinson 1997 bibliographic record

Source

Material type: TF01 bibliography/index
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Direct page returned no readable lines; metadata also corroborated by original reproduction.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
PubMed bibliographic/indexed excerpt Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S03 · Bager et al. 2021. Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease

Source

Material type: Adjacent IBD fatigue RCT
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: The /full address redirected to /abs; encoded /full timed out. Grip text is an indexed excerpt, not full-text verification. Existing fatigue verdict 3086 is unchanged. · Although 600–1,800 mg/day was administered for 4 weeks per period, the population was not recruited for objective weakness, and a quantitative handgrip effect/CI could not be verified. · Denominator: 40 participants; handgrip analysis denominator unverified · Role: Excluded because of the fatigue population/endpoint mismatch
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Publisher abstract/indexed handgrip excerpt Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S04 · Bager 2021 publisher-provided first-page preview

Source

Material type: TF02 first-page/abstract preview
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Only first page and abstract/figure captions read; later citing papers on the same web page are not the original trial.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
ResearchGate first-page preview/abstract Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S05 · Artiukhov et al. 2024. Pharmacological Doses of Thiamine Benefit Patients with the Charcot–Marie–Tooth Neuropathy by Changing Thiamine Diphosphate Levels and Affecting Regulation of Thiamine-Dependent Enzymes

Source

Material type: CMT uncontrolled mixed-treatment report
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Main body subscription-restricted. A healthy metabolic comparison group is not a verified untreated longitudinal grip comparator. · Hydrochloride, sulbutiamine, benfotiamine, and other treatments were not pooled or repurposed as a causal between-group handgrip effect. · Denominator: 15 participants in the supplementary material (14 adults); 5 adults receiving hydrochloride, 2 participants verified in the long-term handgrip figure · Role: Excluded because of the uncontrolled design, mixed formulations, and age mismatch
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Publisher abstract/funding, ethics, and correction metadata Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S06 · Artiukhov 2024 electronic supplementary materials

Source

Material type: CMT supplementary material
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: All 3 pages inspected with PDF screenshots. Mixed ages, thiamine-HCl/derivative exposures and other-therapy rows retained separately. Figure S2 concerns biomarkers, not a grip treatment contrast.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Electronic supplementary PDF, 3 pages Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S07 · Artiukhov 2024 Russian-language report/figure captions

Source

Material type: CMT translation/figures for the same cohort
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Same cohort/translation, not replication. Figure 1 describes patients 1 and 3 receiving thiamine-HCl and patient 2 sulbutiamine; main text restricted.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Russian publisher abstract/figure descriptions Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S08 · Erratum to Artiukhov et al. 2024

Source

Material type: CMT correction notice
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Formal erratum exists; full correction body inaccessible. Main original publisher separately states page-range correction from 1–22 to 1161–1182. Table-3 gray-shading detail was found only in a search excerpt and is not promoted to verified full-text fact.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Publisher correction notice (full text unacquired) Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S09 · Costantini et al. 2016. High-dose thiamine improves the symptoms of myotonic dystrophy type 1

Source

Material type: Two intramuscular DM1 cases
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Two cases, intramuscular thiamine 100 mg twice weekly, not oral single-ingredient controlled dynamometer evidence.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
PMC original-article HTML Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S10 · Smidt et al. 1991. Influence of Thiamin Supplementation on the Health and General Well-being of an Elderly Irish Population With Marginal Thiamin Deficiency

Source

Material type: Well-being trial in healthy older women
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Eighty healthy elderly women; 10 mg/day, six-week double-blind treatment after four-week baseline. Low-strength requirement and isolated objective strength contrast not verified; no benefit borrowed from well-being outcomes.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Publisher indexed abstract Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S11 · Nishiyama et al. 1972. Effect of thiamine tetrahydrofurfuryl disulfide (TTFD) on physical fitness chiefly on muscle strength—double blind studies

Source

Material type: TTFD original-article title
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: TTFD entity exclusion verified from original title. Full paper not extracted; no numerical result asserted.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
J-STAGE original-article landing page Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S12 · Doyle et al. 1997. Allithiamine ingestion does not enhance isokinetic parameters of muscle performance

Source

Material type: Allithiamine isokinetic trial in healthy students
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: 15 healthy college students; oral allithiamine 1 g/day for 5 days, placebo crossover; Biodex System2. Null statistical findings do not establish equivalence and concern a derivative and a different population. · The nonsignificant (P>0.05) result for allithiamine 1 g/day for 5 days does not establish no effect or equivalence for ordinary thiamine, adults with low muscle strength, and handgrip. · Denominator: 15 participants · Role: Excluded because of the derivative, healthy participants, and different muscle-strength endpoint
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
PubMed original-article abstract Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S13 · Ohkoshi et al. 2006. Functional Limitations in Thiamine Deficiency Neuropathy: FIM Score Improvement With Treatment

Source

Material type: Deficiency neuropathy FIM report
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: FIM functional limitation outcome, not verified isolated muscle-strength trial. Detailed methods inaccessible; do not infer oral formulation or comparator.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Indexed abstract excerpt (full-text 402 failure) Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S14 · NIH ODS. Thiamin—Health Professional Fact Sheet

Source

Material type: Official thiamine safety overview
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Canonical address first failed; indexed query-parameter URL yielded full text. Safety context, not efficacy trial evidence.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
NIH official HTML overview Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S15 · Thiamine Hydrochloride 100 mg Tablets—SmPC

Source

Material type: SmPC for a separate 100 mg HCl product
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Product-specific oral hydrochloride; does not establish safety for all products or higher doses. Parenteral predominance of hypersensitivity reports explicitly retained.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
emc official product information Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S16 · Institute of Medicine 1998. Dietary Reference Intakes, Chapter4: Thiamin

Source

Material type: Official dietary-intake/UL chapter
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: No UL because inadequate toxicity data, not proof of unlimited safety. Dialysis/malabsorption may alter requirements; no therapeutic high-dose ceiling derived.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
NCBI official dietary-intake HTML chapter Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S17 · NICE CG32. Nutrition support for adults

Source

Material type: Combined refeeding-management recommendations
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Supervised thiamine within a multi-component nutrition/refeeding regimen; not isolated strength efficacy evidence. Direct main and alternate chapter URLs failed.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
NICE indexed recommendation excerpt (full-page access failed) Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S18 · ClinicalTrials.gov NCT03634735

Source

Material type: TARIF registration-access attempt
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Record identifier verified in original report; official page shell, web API internal error and native API DNS failure. Prospective timing not independently verified.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
ClinicalTrials.gov shell (record body/history unacquired) Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S19 · Bager TARIF family later publications as supplied in prior snapshot3086

Source

Material type: Supplied records of multiple TARIF follow-up reports
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Oral HCl form and same-TARIF metabolic analysis provenance reused solely to map new strength question. PMID34592862 maintenance follow-up also mapped here. No fatigue assessment regraded. User-supplied snapshot, not claimed newly verified original.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Extraction of multiple follow-up reports from previously supplied retained summaries Material URL unverified	Unverified (no external lookup in this work)	Access not attempted	Not read	S19/S21 are entries containing multiple reports/supplied materials; a single external URL is not guaranteed to be a direct full-text link to the same material.

S20 · Bager et al. 2024. High-dose oral thiamine versus placebo for chronic fatigue in primary biliary cholangitis

Source

Material type: PBC fatigue trial
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Different disease and fatigue endpoint; not counted as strength refutation or replication. No fatigue effect size imported.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Indexed abstract excerpt from an original article Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S21 · 2026 B-vitamins/magnesium IBD trial

Source

Material type: Lead for an IBD B-vitamin/magnesium combination trial
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: B1/B6/B12+magnesium combination and fatigue question; ineligible for isolated B1 strength. No new regrading.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Indexed title/previously supplied composition extraction Material URL unverified	Unverified (no external lookup in this work)	Access not attempted	Not read	S19/S21 are entries containing multiple reports/supplied materials; a single external URL is not guaranteed to be a direct full-text link to the same material.

S22 · Thiamine pharmacologic protocols review (evidence map only)

Source

Material type: Review literature map
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Not used for decisive numbers or scoring.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Indexed review excerpt Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

S23 · Association of Micronutrients and Handgrip Strength in Korean Adults

Source

Material type: Dietary micronutrient/handgrip observation
Materials actually read: The designated retained summary was actually read. External/old separate original sources have not been read in the current work.
Findings recorded in the stored summary: Dietary micronutrient association, not an oral single-ingredient intervention; no dietary dose converted to supplement dose.
Record level: A retained summary within the historical extraction/access scope; not new verification of original clinical evidence.
Study overlap and independent replication: Distinguish report, bibliographic/safety, registration, and family roles; do not count 23 entries as 23 trials.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained summary of bibliography, limited extraction, and historical access No external link · retained summary	Locally retained	Acquired	Summary read	Exact stored-manuscript location/value/SHA. Not the original bytes of a clinical full text.
Indexed excerpt from an original observational article Open material ↗	Unverified (no external lookup in this work)	Access not attempted	Not read	Distinguish historical access level/success/failure from current non-attempted external access. The existence of a link is not a current reading record.

Report counts versus independent study counts

These are report links from the stored manuscript. TF01 · near_match_indirect · No objectively weak population or low-strength stratum defined; low TPP and low group-average grip do not establish every participant or a prespecified subgroup had reduced strength. (S01, S02) / TF02 · near_match_indirect · Enrollment on quiescent IBD and severe chronic fatigue; no objectively weak enrollment group or low-strength treatment stratum verified. Handgrip secondary result excerpt does not repair this boundary. (S03, S04, S18, S19) / TF03 · near_match_indirect · No matched untreated/placebo longitudinal grip comparison verified. Mixed forms, durations, ages and outcome denominators are not pooled as a pure oral adult trial. (S05, S06, S07, S08) / TF04 · case_report_injection · IM route, two uncontrolled DM1 cases; not oral dynamometer trial. (S09) / TF05 · healthy_elderly_wellbeing_trial · Healthy elderly women; baseline objective weakness and strength result not verified. (S10) / TF06 · derivative_strength_trial · TTFD is a distinct molecular derivative; not ordinary thiamine. (S11) / TF07 · derivative_healthy_students_trial · Allithiamine, healthy students; do not borrow the nonsignificant isokinetic result. (S12) / TF08 · functional_recovery_report · FIM is general function, not isolated validated strength endpoint; route/comparison unverified. (S13) / TF09 · different_disease_fatigue_trial · PBC fatigue not the target strength endpoint. (S20) / TF10 · combination_fatigue_trial · B-vitamins+magnesium cannot isolate ordinary thiamine strength efficacy. (S21) / TF11 · dietary_observational_study · Dietary micronutrient association not supplement randomization; intake not converted to dose. (S23) The overall unique trial count and total participant count remain unverified. Verification of stored summaries is distinguished from non-reading of original materials in this work; report/family labels are not summed as total trials or participants.

Review criteria

Version 3117-ORAL-THIAMINE-HANDGRIP-1.0 · Criteria record date 2026-10-05. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which population, route, and strength outcome does this table address?

Required materials and conditions: Current independent claim, adults with objectively reduced muscle strength, oral ordinary thiamine, comparator, and handgrip boundary
Conditions for verification: Maintain the same unit of inquiry as the original question and distinguish question-level boundaries from actual trial identity.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not arbitrarily fill in the salt, dose, test, or time point from adjacent studies to resolve the absence of a verified selected trial.
Why this condition is needed: This is needed to avoid combining fatigue, muscle mass, walking, and deficiency treatment with comparative handgrip efficacy.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N02 · Have the ordinary-thiamine salt and single-ingredient product in the target trial been verified?

Required materials and conditions: Base/hydrochloride/nitrate, manufacturer, ingredients/excipients, and free-thiamine-equivalent amount of the product in an eligible original report
Conditions for verification: Retain null values for the actual salt/product and the exclusion of derivatives and combination products separately.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Specifying single-ingredient ordinary thiamine in the question is different from verifying the actual product.
Why this condition is needed: This is needed to avoid identifying the actual trial product from derivatives, a separate licensed product, or mixed CMT treatments.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N03 · Have the question's oral route and the actual tablet/capsule form been distinguished?

Required materials and conditions: Oral route, physical dosage form, and manufacturing/batch data for an eligible comparison
Conditions for verification: Explain the oral question, exclusion of injections, and the gap concerning the actual physical dosage form.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Preserve the oral-route boundary of the question without automatically assigning an unverified tablet/capsule form.
Why this condition is needed: This is needed to avoid transferring responses from injection cases or a specific tablet's product information to the target trial exposure.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N04 · Have the dose and adherence in the target handgrip trial been verified?

Required materials and conditions: Nominal dose, dosing schedule, active amount, actual adherence/exposure, and concomitant supplementation by eligible group
Conditions for verification: Distinguish the null value for the actual target dose from historical doses in individual sources.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Doses in adjacent studies are historical records, not individual dosing recommendations or dose-response evidence.
Why this condition is needed: This is needed to avoid turning 10 mg, 600–1800 mg, or high-dose case reports into effective doses for this population.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N05 · Have the eligible treatment duration and handgrip measurement time point been verified?

Required materials and conditions: Eligible treatment duration, principal handgrip time point, follow-up after discontinuation, and measurements by visit
Conditions for verification: Preserve null actual_duration/actual_timepoint values separately from durations in individual sources.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not replace the question's unverified duration with the duration of an adjacent trial.
Why this condition is needed: This is needed to avoid filling in 3 months, 4 weeks, 5 days, or long-term cases as verified timing for the target question.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N06 · Is there an actual enrollment cutoff for objectively reduced muscle strength?

Required materials and conditions: Adult inclusion/exclusion, definition of objectively reduced handgrip, cutoff, baseline distribution, and verified subgroup
Conditions for verification: Leave the cutoff unverified and explain mismatches in adjacent populations with reference to the original source locations.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Distinguish the question's population definition from verification of an actually eligible population.
Why this condition is needed: This is needed to avoid turning low TPP, older age, fatigue, or a low group mean into reduced muscle strength in every participant.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N07 · Can deficiency correction be separated from the effect of general additional supplementation?

Required materials and conditions: Thiamine status, deficiency definition, handgrip outcomes by status, and deficiency-treatment context in an eligible population
Conditions for verification: Keep actual_thiamine_status null and identify deficiency correction as a separate question.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: This undetermined assessment is not an instruction to stop necessary deficiency treatment.
Why this condition is needed: This is needed to avoid transferring low TPP, deficiency neuropathy, or altered nutritional requirements to the efficacy of general strength supplementation.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N08 · Have the actual comparator and balance of concomitant treatments been verified?

Required materials and conditions: Eligible placebo/no added thiamine/matched usual care, concomitant treatments, changes/rescue treatment, and adherence
Conditions for verification: Record the question's comparison separately from the actual unverified comparator and effects of concomitant interventions.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Distinguish the intended comparator from the null actual_comparator value, without requiring every change in every group to be identical.
Why this condition is needed: This is needed to avoid turning other CMT treatments or healthy-participant biomarker comparisons into handgrip comparators.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N09 · Is there an actual target measurement specifying hand, device, units, and repeated-measurement rules?

Required materials and conditions: Eligible handgrip device/calibration, hand, posture, repetition/aggregation rules, units, assessor masking, and principal time point
Conditions for verification: Distinguish null actual device/hand/unit values from test information in adjacent studies.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The name of an objective measurement alone does not resolve measurement bias or its importance for daily function.
Why this condition is needed: This is needed to avoid filling in dominant-hand measurement with a Preston device as the protocol of an unselected target trial.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N10 · Have the page's handgrip question and the original trial's primary endpoint been distinguished?

Required materials and conditions: Handgrip endpoint, principal time point/analysis hierarchy in eligible registration/planning records, and actual reporting
Conditions for verification: Distinguish handgrip being fixed at the question level from the unverified actual trial hierarchy and plan.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The fact that handgrip is the page's target does not itself mean that it was the trial's primary endpoint or was preregistered.
Why this condition is needed: This is needed to avoid turning a primary fatigue endpoint and a secondary handgrip excerpt into the same prespecified primary handgrip effect.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N11 · Are the 76 older adults with low TPP an objectively weak population?

Required materials and conditions: Wilkinson enrollment criteria, TPP strata, baseline low-handgrip cutoff/prespecified subgroup
Conditions for verification: Retain the trial of 76 participants together with the reasons for the population mismatch.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Low TPP and a low group mean alone do not establish reduced strength in every person or subgroup.
Why this condition is needed: This is needed to avoid promoting the closest controlled trial to a direct trial matching the target population.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N12 · Has the scope of dominant-hand Preston grip measurement and 3 months of exposure been preserved?

Required materials and conditions: S01 testing, units/repetitions, time points, original results tables, and quantitative handgrip contrast
Conditions for verification: Attribute dominant-hand Preston measurement/10 mg/3 months to TF01 and retain the additional measurement gaps.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Historical access to a full-text reproduction on a 3rd-party host differs from reading the local summary in this work.
Why this condition is needed: This is needed to avoid assigning the device/time to another trial or claiming new verification of the complete testing section.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N13 · Does a randomized/double-blind label establish actual implementation?

Required materials and conditions: S01 allocation/concealment, who was masked/masking success, baseline balance, actual adherence, and analysis handling
Conditions for verification: Distinguish the reported parallel design/TPP stratification from unverified implementation details.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not borrow methods from an indirect trial to assign the bias axis of an eligible trial.
Why this condition is needed: This is needed to avoid erasing concealment, deviation, measurement, or selective-reporting problems on the basis of the design's name.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N14 · Are 38 versus 38 and completion by all being turned into a handgrip analysis denominator?

Required materials and conditions: Allocation/completion, handgrip measurement and analysis denominators, missingness, and variance/intervals
Conditions for verification: Distinguish original participation/completion records from unverified handgrip analyses and effect intervals.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Retain the existing record of 76, 38/38, and completion by all without creating new sums.
Why this condition is needed: This is needed to avoid assuming from participation/completion counts alone that all handgrip observations and analyses involve the same numbers.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N15 · Is handgrip nonsignificance being read as an effect of 0 or equivalence?

Required materials and conditions: Original handgrip treatment contrast, variance, CI, exact P, and analysis population/model
Conditions for verification: Preserve the nonsignificant report together with unverified numerical values/intervals, and do not make new calculations.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The statement that a quantitative contrast was not reported is limited to the retained extraction currently read.
Why this condition is needed: This is needed to avoid turning a statement about significance into a quantitative effect magnitude or exclusion of benefit.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N16 · Is funding from indirect trials being borrowed as independent efficacy replication?

Required materials and conditions: TF01/TF02/TF03 funding, product provision, author declarations/patents, and family relationships
Conditions for verification: Distinguish retained funding and not-reported/unverified provision information from the currently unscored independence axis.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not automatically exclude a study because funding exists or establish bias because it is unknown.
Why this condition is needed: This is needed to avoid turning the names of public/private funders into absence of product provision or conflicts of interest, or into independent replication.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N17 · Is a handgrip excerpt from an IBD-fatigue crossover trial the target result?

Required materials and conditions: TARIF baseline reduced-strength enrollment/strata, handgrip analysis results, and fatigue/handgrip hierarchy
Conditions for verification: Separate the existence of the 40-participant fatigue trial from gaps concerning the target population and quantitative handgrip results.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not modify existing fatigue verdict 3086 or borrow it to score handgrip efficacy.
Why this condition is needed: This is needed to avoid turning severe chronic fatigue and a secondary handgrip excerpt into a direct effect in an objectively weak population.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N18 · Are the 40 participants across two periods being counted as independent participants or a between-group handgrip effect?

Required materials and conditions: 4-week treatment, 4-week washout, sequence/period, paired data, handgrip analysis counts, and carryover/model
Conditions for verification: Distinguish the retained schedule and nominal dose from unverified handgrip-specific analysis.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not create an eligible crossover estimand while population/endpoint mismatches remain unresolved.
Why this condition is needed: This is needed to avoid summing crossover participants as new people in each period or borrowing fatigue analysis as handgrip analysis.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N19 · Have the NCT identifier and actual reading of the plan/amendment history been distinguished?

Required materials and conditions: Structured content of NCT03634735, original registration timing, handgrip hierarchy/analysis, and amendment history
Conditions for verification: Preserve verification of the identifier and unverified content/history, without newly assigning a current Inaccessible status.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Distinguish historical shell/API/DNS failures from external access not attempted in this work.
Why this condition is needed: This is needed to avoid turning a registration number into prospective registration or completion of selective-reporting assessment.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N20 · Is the supplied 3086 extraction being read as new full-text reading or independent replication?

Required materials and conditions: Original identities of subsequent metabolic/maintenance reports, common family/population, and handgrip endpoint/access
Conditions for verification: Distinguish the historical supplied-material/multiple-report role of S19 from unverified handgrip results.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not record that older protected_input files or external subsequent full texts were opened in this work.
Why this condition is needed: This is needed to avoid counting the hydrochloride lead in previously supplied material and subsequent fatigue analyses as new handgrip trials.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N21 · Are the 15, 14, 5, and 2 participants counted as the same trial of a pure oral preparation in adults?

Required materials and conditions: Age, formulation, other treatments, and participants/denominators for handgrip follow-up in each row of the CMT supplementary material
Conditions for verification: Preserve the supplementary material's 15 participants/14 adults, 5 adult HCl rows, and 2 participants with long-term HCl handgrip observations according to their respective roles.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The existing denominators are historical extractions; no additional totals or effect calculations are generated in this work.
Why this condition is needed: Needed to avoid combining mixed formulations, a participant aged 16, other treatments, and different denominators into a single oral-treatment result in adults.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N22 · Were HCl in patients 1 and 3 distinguished from sulbutiamine in patient 2?

Required materials and conditions: Patient-specific formulations, durations, handgrip follow-up, concomitant treatments/controls, and original measurements in Figure 1
Conditions for verification: Preserve individual formulations and uncontrolled follow-up without repurposing them as comparative efficacy evidence.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The Russian/English reports concern the same cohort/translation and are not independent replications.
Why this condition is needed: Needed to avoid converting favorable before-and-after observations into a causal between-group effect of ordinary thiamine.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N23 · Is a healthy-person biomarker comparison an untreated handgrip control?

Required materials and conditions: Actual comparators, tests, and time points for the biomarker comparison/Figure S2 and long-term handgrip observations
Conditions for verification: Record the comparative meaning of biomarkers and handgrip, and the unverified control, separately.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Distinguish the historical record of visual review of 3 supplementary PDF pages from the current reading of the summary.
Why this condition is needed: Needed to avoid importing healthy controls for different outcomes/time points into the same handgrip efficacy comparison.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N24 · Were the existence of a correction and verification of its actual full text distinguished?

Required materials and conditions: Original/corrected versions, page changes, scope of text/table corrections, and effects on attribution of handgrip observations
Conditions for verification: Preserve the historical correction notice, page correction, unacquired full text, and excerpt limitations.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not count a correction within the same family as a new trial or use the gray-shading excerpt as a verified fact.
Why this condition is needed: Needed to avoid treating a bibliographic correction, inaccessible full text, or search excerpt as a fully verified clinical correction.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N25 · Are the two DM1 cases being read as an oral-treatment handgrip comparison?

Required materials and conditions: Actual route, 100 mg 2 times per week, symptoms/measurements, and presence or absence of a control in the DM1 cases
Conditions for verification: Indicate the 2 cases, injection route, uncontrolled design, and current non-reading of the external full text.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Preserve the existence of the cases rather than recasting it as an absence of human research; distinguish only their eligibility for the target question.
Why this condition is needed: Needed to avoid transferring uncontrolled improvement with intramuscular injections to an effect of single-ingredient oral treatment on handgrip.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N26 · Is well-being in healthy older women being transferred to a handgrip effect in people with low muscle strength?

Required materials and conditions: Smidt's baseline definition of low muscle strength, handgrip results, health/well-being endpoints, and denominators
Conditions for verification: Distinguish the context of 80 participants/10 mg/6 weeks and a 4-week baseline from gaps in the target population/endpoint.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Preserve the existence of the original trial in healthy participants without newly importing an effect size.
Why this condition is needed: Needed to avoid treating older age, marginal thiamine status, and improved well-being as the same handgrip outcome in objectively weak participants.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N27 · Are the TTFD title and landing page being read as numerical evidence for ordinary thiamine?

Required materials and conditions: Original molecular identity, title/material type, and level of access to actual population/measurement results
Conditions for verification: Preserve both the molecular exclusion of TTFD and the lack of extraction of original numerical results.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not turn 'double blind' in a title into a complete extraction of methods/numbers.
Why this condition is needed: Needed to avoid pooling a derivative and an original article verified only at title level with handgrip effects of ordinary thiamine.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N28 · Is an isokinetic P>0.05 in healthy participants being read as no handgrip effect?

Required materials and conditions: Allithiamine, 15 healthy students, 5 days/1 g, Biodex isokinetic results, and original intervals
Conditions for verification: Indicate differences in molecule/population/endpoint together with the limitations of nonsignificance.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The existing P>0.05 is a historical report; no exact P value or equivalence interval is generated.
Why this condition is needed: Needed to avoid converting nonsignificance for a derivative, a different population, and a different muscle-strength endpoint into a target effect of 0.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N29 · Were FIM recovery, actual handgrip, and an oral-treatment comparison distinguished?

Required materials and conditions: FIM results, actual route/comparator, separate handgrip testing, and access to original methods
Conditions for verification: Retain the general functional endpoint and unverified route/methods.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not infer an oral preparation/comparator from inaccessible methods.
Why this condition is needed: Needed to avoid transferring overall function in deficiency neuropathy to an isolated handgrip outcome.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N30 · Do PBC fatigue and B-vitamin/magnesium results replicate a single-ingredient handgrip effect?

Required materials and conditions: The disease/endpoint in S20 and the combined ingredients/fatigue question and original access in S21
Conditions for verification: Preserve differences in disease/endpoint/ingredient eligibility for each source.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not borrow effect sizes or rescore the existing fatigue assessment.
Why this condition is needed: Needed to avoid attributing results for fatigue in another disease or for a combined intervention to ordinary thiamine alone for handgrip.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N31 · Is a micronutrient association in Korean adults being recast as supplementation efficacy?

Required materials and conditions: Dietary observational design, direction of the exposure/handgrip association, and presence or absence of an actual randomized supplementation comparison
Conditions for verification: Indicate the difference between questions about observational associations and intervention comparisons.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not calculate a supplementation dose from dietary intake in this work or import the original observational effect.
Why this condition is needed: Needed to avoid converting a dietary-intake association into a single-ingredient treatment or a supplementation dose/need.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N32 · How should 23 sources, 11 families, and 0 directly eligible comparisons be interpreted?

Required materials and conditions: Links from report to study/case family to endpoint/time point; provisionally related reports; duplication/unique counts
Conditions for verification: Distinguish the current structural family/report relationships from unverified overall unique study/participant counts.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not treat the TF01 lead for potentially shared recruitment of 222 people as a verified independent trial or an additional denominator.
Why this condition is needed: Needed to avoid counting bibliographic records, registrations, safety sources, reviews, and access attempts as 23 trials, or converting 0 directly eligible comparisons into 0 human studies.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N33 · Is an unverified effect being filled in using within-group changes or baseline handgrip?

Required materials and conditions: Eligible between-group handgrip estimand; ITT/PP/adjustment; original effect/CI/exact P; denominators
Conditions for verification: Keep primary_effect/CI/P null and no_effect_claim=false.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not fill invalid raw calculation suggestions or an eligibility-schema gap with an effect of 0.
Why this condition is needed: Needed to avoid constructing a target causal effect from baseline values, nonsignificance, or favorable before-and-after observations in adjacent studies.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N34 · Does objective handgrip guarantee a benefit in daily function or clinical events?

Required materials and conditions: Eligible handgrip interval, justified important difference, meaning of the test, and separate daily-function outcomes
Conditions for verification: Distinguish unverified importance/intervals and test meaning from separate function/event questions.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not assign an unsupported MCID, required participant count/duration, or P/S as new numbers/axes.
Why this condition is needed: Needed to avoid arbitrarily establishing patient-important benefit, H/P, or equivalence from objectivity, significance, or sample size.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N35 · Is selective reporting being established merely because an eligible registration/plan is unavailable?

Required materials and conditions: Eligible original registration/protocol/analysis plan, endpoints/time points, reasons for changes, and corrected versions
Conditions for verification: Indicate the actual eligible plan that could not be compared and access limitations for adjacent materials.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not use unverified TF01/TF03 registrations or the TARIF identifier as verification of an eligible plan.
Why this condition is needed: Needed to avoid converting unacquired plans into confirmed non-registration, selective reporting, or absence of original results.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N36 · Does a separate 100 mg SmPC provide the safety denominator for the target exposure?

Required materials and conditions: Product-specific adverse reactions/frequencies in S15; eligible actual exposure/duration and population; collection, discontinuations, and denominators
Conditions for verification: Distinguish product-specific reactions from unverified target frequencies/denominators and doses safe for long-term use.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Preserve existing cautions without deleting the efficacy manuscript because of gaps in harm information.
Why this condition is needed: Needed to avoid transferring precautions for an authorized product to individual safety or incidence in the target handgrip trial.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N37 · Are injection-related hypersensitivity and product-specific pregnancy/pediatric restrictions being generalized?

Required materials and conditions: Route of hypersensitivity reactions, product-specific pregnancy/lactation and age recommendations, and applicability to populations
Conditions for verification: Indicate historical cautions limited to the route/product/population without claiming established safety.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not extend the adult handgrip question to children or pregnancy.
Why this condition is needed: Needed to avoid turning an injection-related anaphylaxis risk rate or product restrictions into contraindications to all oral nutritional intake.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N38 · Do dialysis, malabsorption, and refeeding management establish the benefit of general handgrip supplementation?

Required materials and conditions: Drug interactions, requirements in dialysis/malabsorption, and actual medical management of alcohol-related deficiency/refeeding
Conditions for verification: Distinguish the original medical/drug context from separate gaps in efficacy/safety.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not assert an absence of interactions or interpret this as an instruction to stop necessary deficiency treatment.
Why this condition is needed: Needed to avoid converting different requirements or combined medical management into high-dose oral handgrip efficacy or a safety upper limit.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N39 · Are the absence of an established UL and water solubility being read as unlimited safety?

Required materials and conditions: Reason no UL was established, actual toxicity data, safety by population/dose/duration, and harm denominators
Conditions for verification: Record both the reason no limit was established and the unverified therapeutic dose/long-term safety.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not propose unsupported numerical safety limits or doses.
Why this condition is needed: Needed to avoid turning insufficient data, water solubility, or excretion into a guarantee of high-dose safety for an individual.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N40 · Are data on optimal dose, maintenance, subgroups, and falls/mortality being imposed as mandatory for this table?

Required materials and conditions: Identity and direct evidence for the original handgrip question and separate dose, maintenance, function, and event extensions
Conditions for verification: Do not impose the extensions themselves as requirements for the current question; distinguish them from actual exposure/denominator gaps.
Requirement and applicability: Supplementary (required if a separate expanded claim is made)
Application exceptions: Do not turn unverified exposure/duration essential to the original comparative handgrip question into NA.
Why this condition is needed: Needed to avoid requiring every extension study for a narrow, unresolved handgrip question or expanding an adjacent main effect.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N41 · Is unverified eligibility in the recorded search being declared an absence of human research?

Required materials and conditions: The 2026-09-16 search/cutoff date, actual inputs/failures, and scope for unpublished studies, registrations, corrections, and retractions
Conditions for verification: Distinguish the scope of the historical search/literature map and current local reading from incomplete external verification.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Do not label the absence of external searching in this work or unacquired full texts as 0 studies or no recent corrections.
Why this condition is needed: Needed to avoid overstating the scope of an old search and the current table conversion as an up-to-date comprehensive search.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N42 · Are the original ?/null, document A, and calculator exception being read as new evidence?

Required materials and conditions: Original grade/score, unscored axes, eligibility exception, document evaluation, and reviewer identity
Conditions for verification: Preserve the original ?/null/Caution, document A/self-review, and human_study_exists=true.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The invalid raw suggestion and calculator-schema problem are historical records, not a calculator run/reassessment in this work.
Why this condition is needed: Needed to avoid changing the original current values into a score of 0, no effect, no human research, or independent clinical certification.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N43 · Are summary reading and historical full-text access being shown as the same verification?

Required materials and conditions: Physical type, historical access level/location, current non-reading, and retained-summary pointer/literal/SHA for each material
Conditions for verification: Link summaries to exact retained locations and indicate current non-attempted/non-read external access and the absence of preserved original bytes.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: The stored-manuscript SHA is not a hash of the original bytes of an external PDF/original article.
Why this condition is needed: Needed to avoid turning local-summary reading or historical 3rd-party full-text/abstract access or registration-access failures into current reading of original clinical sources.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

N44 · Is historical deployment metadata being read as publication in this work?

Required materials and conditions: Current ID/URL, evidence/review dates, original revision/deployment metadata, and links between update events/criteria versions
Conditions for verification: Distinguish current identity/original dates from this review/unpublished status and establish update rules for linked rows.
Requirement and applicability: Required (selected handgrip question)
Application exceptions: Preserve original materials, unfavorable results, unverified information, and assessments; record changed conditions and new evidence separately.
Why this condition is needed: Needed to avoid presenting historical site deployment and current local-sheet creation as the same completion.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility criteria and reasons for changes, and distinguish variations in the intervention.
Extent of review: Records reuse of retained methodological principles/versions and the 5 actual HTML copies from 1585. This is not new reading of methodological full texts or an official execution/certification in the current work.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish and link studies and reports, and do not omit a study solely because its outcomes are not reported.
Extent of review: Records reuse of retained methodological principles/versions and the 5 actual HTML copies from 1585. This is not new reading of methodological full texts or an official execution/certification in the current work.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Hold the outcome and effect of interest fixed, then assess randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Records reuse of retained methodological principles/versions and the 5 actual HTML copies from 1585. This is not new reading of methodological full texts or an official execution/certification in the current work.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Records reuse of retained methodological principles/versions and the 5 actual HTML copies from 1585. This is not new reading of methodological full texts or an official execution/certification in the current work.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Questions about harms may require designs, populations and follow-up different from efficacy questions. Case reports do not establish incidence.
Extent of review: Records reuse of retained methodological principles/versions and the 5 actual HTML copies from 1585. This is not new reading of methodological full texts or an official execution/certification in the current work.

What the statuses mean

Partly verified: Some retained information exists, but gaps remain in eligible populations/exposures, measurements/denominators/estimates, original-source access, and related details.
Unverified: The necessary information/conditions cannot be established within the current verification scope.
Review incomplete: Original-material comparison/search was not performed within the permitted scope.
Not reported: A scope-limited status indicating that the item was not stated in the particular material/section read.
Inaccessible: Used only for materials for which access was actually attempted and failed. Not assigned to clinical materials in the current work.
Insufficient eligible evidence: Used only when, after reviewing related studies within a defined scope, evidence is insufficient to answer the specified question. Not applied across all entries in this work.
Not applicable: Specific non-applicability: separate extension studies are not imposed on the current narrow handgrip question. Not a substitute for unverified actual exposure/population/outcomes.
Conflicting information: Used when incompatible information has been compared for the same question, time point, and analysis. Not assigned merely because numbers differ between reviews.
Met: Verification of the stated preservation, boundary/distinction, or linkage conditions. Not certification of clinical efficacy, external full-text reading, or individual safety.

Change history

2026-11-06 · Public page/material version 1.0

Public-facing display and data were prepared from the existing 44 items. No new clinical search, verification-status change, or scoring was performed.

The stored-material review date (2026-10-05) and original evidence cut-off (2026-09-16) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which population, route, and strength outcome does this table address?

Current findings: The current claim is a single comparative handgrip question about single-ingredient oral ordinary thiamine in adults with objectively reduced muscle strength. The source explicitly specifies a single independent claim, and no actual trial has been fixed. The original stored summary has no subclaims key.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies preservation of the claim boundary. It does not mean that a directly eligible trial or effect has been verified.
Reason for missing information: This verifies preservation of the claim boundary. It does not mean that a directly eligible trial or effect has been verified.
Required materials and conditions: Current independent claim, adults with objectively reduced muscle strength, oral ordinary thiamine, comparator, and handgrip boundary
Materials to obtain first: Current independent claim, adults with objectively reduced muscle strength, oral ordinary thiamine, comparator, and handgrip boundary
Further research: Verify comparative handgrip data that meet this boundary, and assess other endpoints and formulations as separate questions.
Remaining uncertainty: This verifies preservation of the claim boundary. It does not mean that a directly eligible trial or effect has been verified.
Conditions for verification: Maintain the same unit of inquiry as the original question and distinguish question-level boundaries from actual trial identity.
Why this condition is needed: This is needed to avoid combining fatigue, muscle mass, walking, and deficiency treatment with comparative handgrip efficacy.
Application exceptions: Do not arbitrarily fill in the salt, dose, test, or time point from adjacent studies to resolve the absence of a verified selected trial.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources

N02 · Have the ordinary-thiamine salt and single-ingredient product in the target trial been verified?

Current findings: The question concerns single-ingredient ordinary thiamine, but no eligible study has been selected, so the actual salt and product are unverified. The actual_salt field in the assessment question's identity is null. It was not filled using the mixture of CMT hydrochloride and derivative exposures or the separate 100 mg product in S15.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The eligible product and actual chemical form cannot be identified within the current retained scope.
Reason for missing information: The eligible product and actual chemical form cannot be identified within the current retained scope.
Required materials and conditions: Base/hydrochloride/nitrate, manufacturer, ingredients/excipients, and free-thiamine-equivalent amount of the product in an eligible original report
Materials to obtain first: Base/hydrochloride/nitrate, manufacturer, ingredients/excipients, and free-thiamine-equivalent amount of the product in an eligible original report
Further research: Compare product and ingredient records from an eligible trial, and extract derivative/combination exposures separately.
Remaining uncertainty: The eligible product and actual chemical form cannot be identified within the current retained scope.
Conditions for verification: Retain null values for the actual salt/product and the exclusion of derivatives and combination products separately.
Why this condition is needed: This is needed to avoid identifying the actual trial product from derivatives, a separate licensed product, or mixed CMT treatments.
Application exceptions: Specifying single-ingredient ordinary thiamine in the question is different from verifying the actual product.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S05 S06 S11 S15

N03 · Have the question's oral route and the actual tablet/capsule form been distinguished?

Current findings: The claim's route is oral, and injections are not allowed. The physical dosage form of an actually eligible product is unverified. The intramuscular 100 mg, 2 times per week cases in S09 and the tablets in S15 were not used as the oral product in the target handgrip trial.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The route boundary is clear, but the actual eligible product and physical dosage form have not been verified.
Reason for missing information: The route boundary is clear, but the actual eligible product and physical dosage form have not been verified.
Required materials and conditions: Oral route, physical dosage form, and manufacturing/batch data for an eligible comparison
Materials to obtain first: Oral route, physical dosage form, and manufacturing/batch data for an eligible comparison
Further research: Verify administration and physical dosage form in the original trial, and link injection and derivative evidence separately.
Remaining uncertainty: The route boundary is clear, but the actual eligible product and physical dosage form have not been verified.
Conditions for verification: Explain the oral question, exclusion of injections, and the gap concerning the actual physical dosage form.
Why this condition is needed: This is needed to avoid transferring responses from injection cases or a specific tablet's product information to the target trial exposure.
Application exceptions: Preserve the oral-route boundary of the question without automatically assigning an unverified tablet/capsule form.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S09 S15

N04 · Have the dose and adherence in the target handgrip trial been verified?

Current findings: The actual_dose and verified_values.dose fields for an eligible handgrip comparison are null. Wilkinson's 10 mg/day and TARIF's 600–1800 mg/day are historical exposures in different populations/outcomes. No dose conversion, calculation, or dosing suggestion was made in this work.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Actual dose, schedule, adherence, and handgrip outcomes by dose for the target comparison are unverified.
Reason for missing information: Actual dose, schedule, adherence, and handgrip outcomes by dose for the target comparison are unverified.
Required materials and conditions: Nominal dose, dosing schedule, active amount, actual adherence/exposure, and concomitant supplementation by eligible group
Materials to obtain first: Nominal dose, dosing schedule, active amount, actual adherence/exposure, and concomitant supplementation by eligible group
Further research: Link dosing/adherence records for an eligible product to outcome denominators, and assess direct dose comparisons separately.
Remaining uncertainty: Actual dose, schedule, adherence, and handgrip outcomes by dose for the target comparison are unverified.
Conditions for verification: Distinguish the null value for the actual target dose from historical doses in individual sources.
Why this condition is needed: This is needed to avoid turning 10 mg, 600–1800 mg, or high-dose case reports into effective doses for this population.
Application exceptions: Doses in adjacent studies are historical records, not individual dosing recommendations or dose-response evidence.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S03

N05 · Have the eligible treatment duration and handgrip measurement time point been verified?

Current findings: The treatment duration and principal handgrip time point of a selected eligible trial are null. Wilkinson's 3 months, TARIF's 4-week periods and washout, and allithiamine's 5 days were not combined as target efficacy over the same period.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The appropriate duration, principal time point, and sustained effect for the target handgrip comparison have not yet been verified.
Reason for missing information: The appropriate duration, principal time point, and sustained effect for the target handgrip comparison have not yet been verified.
Required materials and conditions: Eligible treatment duration, principal handgrip time point, follow-up after discontinuation, and measurements by visit
Materials to obtain first: Eligible treatment duration, principal handgrip time point, follow-up after discontinuation, and measurements by visit
Further research: Verify visit, treatment, and discontinuation times in an eligible comparison, and assess maintenance effects using separate data.
Remaining uncertainty: The appropriate duration, principal time point, and sustained effect for the target handgrip comparison have not yet been verified.
Conditions for verification: Preserve null actual_duration/actual_timepoint values separately from durations in individual sources.
Why this condition is needed: This is needed to avoid filling in 3 months, 4 weeks, 5 days, or long-term cases as verified timing for the target question.
Application exceptions: Do not replace the question's unverified duration with the duration of an adjacent trial.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S03 S12

N06 · Is there an actual enrollment cutoff for objectively reduced muscle strength?

Current findings: The target is adults with objectively reduced muscle strength, but actual_weakness_cutpoint is null. Older adults with low TPP in TF01, IBD patients with fatigue in TF02, and healthy students do not automatically meet that definition.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The eligible reduced-strength cutoff, baseline distribution, and selected subgroup are unverified.
Reason for missing information: The eligible reduced-strength cutoff, baseline distribution, and selected subgroup are unverified.
Required materials and conditions: Adult inclusion/exclusion, definition of objectively reduced handgrip, cutoff, baseline distribution, and verified subgroup
Materials to obtain first: Adult inclusion/exclusion, definition of objectively reduced handgrip, cutoff, baseline distribution, and verified subgroup
Further research: Obtain enrollment criteria, individual/subgroup baseline handgrip, and prespecified definitions before comparing population eligibility.
Remaining uncertainty: The eligible reduced-strength cutoff, baseline distribution, and selected subgroup are unverified.
Conditions for verification: Leave the cutoff unverified and explain mismatches in adjacent populations with reference to the original source locations.
Why this condition is needed: This is needed to avoid turning low TPP, older age, fatigue, or a low group mean into reduced muscle strength in every participant.
Application exceptions: Distinguish the question's population definition from verification of an actually eligible population.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S03 S12

N07 · Can deficiency correction be separated from the effect of general additional supplementation?

Current findings: Thiamine status in an actually eligible population is null. Selection for low erythrocyte TPP and objectively reduced muscle strength are different criteria, and deficiency correction or refeeding management does not replace evidence of efficacy for general handgrip supplementation.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Nutritional status and effects by deficient/nondeficient status in the target comparison have not been verified.
Reason for missing information: Nutritional status and effects by deficient/nondeficient status in the target comparison have not been verified.
Required materials and conditions: Thiamine status, deficiency definition, handgrip outcomes by status, and deficiency-treatment context in an eligible population
Materials to obtain first: Thiamine status, deficiency definition, handgrip outcomes by status, and deficiency-treatment context in an eligible population
Further research: Compare status definitions, treatment context, and direct handgrip comparisons by status separately.
Remaining uncertainty: Nutritional status and effects by deficient/nondeficient status in the target comparison have not been verified.
Conditions for verification: Keep actual_thiamine_status null and identify deficiency correction as a separate question.
Why this condition is needed: This is needed to avoid transferring low TPP, deficiency neuropathy, or altered nutritional requirements to the efficacy of general strength supplementation.
Application exceptions: This undetermined assessment is not an instruction to stop necessary deficiency treatment.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S16 S17

N08 · Have the actual comparator and balance of concomitant treatments been verified?

Current findings: The question's comparators are placebo, no added thiamine, or usual care with all other treatments matched. The actually eligible comparator is null. Mixed CMT formulations/other treatments and healthy-participant biomarker comparisons are not matched untreated long-term handgrip comparators.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Group-specific concomitant-treatment and exposure data needed to distinguish the eligible comparison and the selected thiamine's contribution are unverified.
Reason for missing information: Group-specific concomitant-treatment and exposure data needed to distinguish the eligible comparison and the selected thiamine's contribution are unverified.
Required materials and conditions: Eligible placebo/no added thiamine/matched usual care, concomitant treatments, changes/rescue treatment, and adherence
Materials to obtain first: Eligible placebo/no added thiamine/matched usual care, concomitant treatments, changes/rescue treatment, and adherence
Further research: Link background care and changes by group to the analysis of the actual effect of interest.
Remaining uncertainty: Group-specific concomitant-treatment and exposure data needed to distinguish the eligible comparison and the selected thiamine's contribution are unverified.
Conditions for verification: Record the question's comparison separately from the actual unverified comparator and effects of concomitant interventions.
Why this condition is needed: This is needed to avoid turning other CMT treatments or healthy-participant biomarker comparisons into handgrip comparators.
Application exceptions: Distinguish the intended comparator from the null actual_comparator value, without requiring every change in every group to be identical.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S05 S06 S07

N09 · Is there an actual target measurement specifying hand, device, units, and repeated-measurement rules?

Current findings: For the target handgrip outcome, actual_device, actual_hand, actual_units, and the principal time point are null. Dominant-hand Preston measurement in TF01 is adjacent-trial information and does not automatically establish repeated-measurement rules or the target protocol.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Actual measurement, aggregation, group-specific assessment conditions, and units for the target handgrip outcome are unverified.
Reason for missing information: Actual measurement, aggregation, group-specific assessment conditions, and units for the target handgrip outcome are unverified.
Required materials and conditions: Eligible handgrip device/calibration, hand, posture, repetition/aggregation rules, units, assessor masking, and principal time point
Materials to obtain first: Eligible handgrip device/calibration, hand, posture, repetition/aggregation rules, units, assessor masking, and principal time point
Further research: Extract eligible testing procedures and implementation/assessment by group together with the original handgrip results.
Remaining uncertainty: Actual measurement, aggregation, group-specific assessment conditions, and units for the target handgrip outcome are unverified.
Conditions for verification: Distinguish null actual device/hand/unit values from test information in adjacent studies.
Why this condition is needed: This is needed to avoid filling in dominant-hand measurement with a Preston device as the protocol of an unselected target trial.
Application exceptions: The name of an objective measurement alone does not resolve measurement bias or its importance for daily function.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01

N10 · Have the page's handgrip question and the original trial's primary endpoint been distinguished?

Current findings: The question-level endpoint is fixed as handgrip. No directly eligible trial has been selected, and the actual prespecified endpoint hierarchy is unverified. TARIF remains in the context of primary fatigue and an excerpt concerning secondary handgrip.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The page's endpoint is clear, but comparison of eligible prespecified hierarchy with reporting is incomplete.
Reason for missing information: The page's endpoint is clear, but comparison of eligible prespecified hierarchy with reporting is incomplete.
Required materials and conditions: Handgrip endpoint, principal time point/analysis hierarchy in eligible registration/planning records, and actual reporting
Materials to obtain first: Handgrip endpoint, principal time point/analysis hierarchy in eligible registration/planning records, and actual reporting
Further research: Compare registration, protocol, and analysis plan with actual handgrip reporting.
Remaining uncertainty: The page's endpoint is clear, but comparison of eligible prespecified hierarchy with reporting is incomplete.
Conditions for verification: Distinguish handgrip being fixed at the question level from the unverified actual trial hierarchy and plan.
Why this condition is needed: This is needed to avoid turning a primary fatigue endpoint and a secondary handgrip excerpt into the same prespecified primary handgrip effect.
Application exceptions: The fact that handgrip is the page's target does not itself mean that it was the trial's primary endpoint or was preregistered.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S03 S18

N11 · Are the 76 older adults with low TPP an objectively weak population?

Current findings: Wilkinson is a placebo-controlled study of 10 mg/day for 3 months in 76 older adults. The entry criterion was erythrocyte TPP <140 nmol/L, not an objective reduced-strength cutoff. It was therefore not selected as directly eligible for the current target efficacy question.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The trial exists, but a direct comparison in an objectively weak population or prespecified stratum has not been verified.
Reason for missing information: The trial exists, but a direct comparison in an objectively weak population or prespecified stratum has not been verified.
Required materials and conditions: Wilkinson enrollment criteria, TPP strata, baseline low-handgrip cutoff/prespecified subgroup
Materials to obtain first: Wilkinson enrollment criteria, TPP strata, baseline low-handgrip cutoff/prespecified subgroup
Further research: Verify original enrollment, baseline handgrip, and prespecified comparisons by stratum to prepare material for reassessing eligibility.
Remaining uncertainty: The trial exists, but a direct comparison in an objectively weak population or prespecified stratum has not been verified.
Conditions for verification: Retain the trial of 76 participants together with the reasons for the population mismatch.
Why this condition is needed: This is needed to avoid promoting the closest controlled trial to a direct trial matching the target population.
Application exceptions: Low TPP and a low group mean alone do not establish reduced strength in every person or subgroup.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S02

N12 · Has the scope of dominant-hand Preston grip measurement and 3 months of exposure been preserved?

Current findings: The retained TF01 record describes dominant-hand grip with a Preston dynamometer and oral 10 mg/day for 3 months. S01 was an HTML reproduction of the original report on a 3rd-party host at that time, with recorded layout errors in text extraction from the two-column article. The original clinical full text was not reread in this work.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Testing and duration information is retained, but the quantitative contrast, applicability of units/repetition procedures to the target, and current comparison with the original text are unverified.
Reason for missing information: Testing and duration information is retained, but the quantitative contrast, applicability of units/repetition procedures to the target, and current comparison with the original text are unverified.
Required materials and conditions: S01 testing, units/repetitions, time points, original results tables, and quantitative handgrip contrast
Materials to obtain first: S01 testing, units/repetitions, time points, original results tables, and quantitative handgrip contrast
Further research: Verify testing procedures and analysis values in the original Methods/Results/tables, and link them to the same outcome.
Remaining uncertainty: Testing and duration information is retained, but the quantitative contrast, applicability of units/repetition procedures to the target, and current comparison with the original text are unverified.
Conditions for verification: Attribute dominant-hand Preston measurement/10 mg/3 months to TF01 and retain the additional measurement gaps.
Why this condition is needed: This is needed to avoid assigning the device/time to another trial or claiming new verification of the complete testing section.
Application exceptions: Historical access to a full-text reproduction on a 3rd-party host differs from reading the local summary in this work.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01

N13 · Does a randomized/double-blind label establish actual implementation?

Current findings: TF01 is recorded as a randomized double-blind placebo-controlled parallel trial stratified by pretreatment TPP status. The current input is not independent verification of actual concealment, masking success, or adherence by group.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The design is reported, but information is insufficient to establish actual implementation/adherence or outcome-specific bias.
Reason for missing information: The design is reported, but information is insufficient to establish actual implementation/adherence or outcome-specific bias.
Required materials and conditions: S01 allocation/concealment, who was masked/masking success, baseline balance, actual adherence, and analysis handling
Materials to obtain first: S01 allocation/concealment, who was masked/masking success, baseline balance, actual adherence, and analysis handling
Further research: Compare the original methods with baseline, implementation, and analysis information for the handgrip outcome of interest.
Remaining uncertainty: The design is reported, but information is insufficient to establish actual implementation/adherence or outcome-specific bias.
Conditions for verification: Distinguish the reported parallel design/TPP stratification from unverified implementation details.
Why this condition is needed: This is needed to avoid erasing concealment, deviation, measurement, or selective-reporting problems on the basis of the design's name.
Application exceptions: Do not borrow methods from an indirect trial to assign the bias axis of an eligible trial.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01

N14 · Are 38 versus 38 and completion by all being turned into a handgrip analysis denominator?

Current findings: The retained TF01 evidence records 76 participants, 38 thiamine/38 placebo, and completion by all. These were not automatically used as the analysis count for the target eligible population or the number of handgrip observations at every time point. The eligible handgrip effect/CI are null.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The verification levels of participation/completion information and handgrip-specific analysis denominators/intervals differ.
Reason for missing information: The verification levels of participation/completion information and handgrip-specific analysis denominators/intervals differ.
Required materials and conditions: Allocation/completion, handgrip measurement and analysis denominators, missingness, and variance/intervals
Materials to obtain first: Allocation/completion, handgrip measurement and analysis denominators, missingness, and variance/intervals
Further research: Link measurement/analysis counts at each time point in the original handgrip tables with missing-data handling and variance definitions.
Remaining uncertainty: The verification levels of participation/completion information and handgrip-specific analysis denominators/intervals differ.
Conditions for verification: Distinguish original participation/completion records from unverified handgrip analyses and effect intervals.
Why this condition is needed: This is needed to avoid assuming from participation/completion counts alone that all handgrip observations and analyses involve the same numbers.
Application exceptions: Retain the existing record of 76, 38/38, and completion by all without creating new sums.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01

N15 · Is handgrip nonsignificance being read as an effect of 0 or equivalence?

Current findings: The retained Wilkinson record states that handgrip did not change significantly, but provides no quantitative treatment contrast, CI, or exact P. The historical extraction stating that Table 3 lacks a handgrip-change contrast is preserved, and no conclusion of no effect or equivalence was made.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: There is a statement of nonsignificance, but magnitude, precision, and exclusion of a meaningful benefit have not been verified.
Reason for missing information: There is a statement of nonsignificance, but magnitude, precision, and exclusion of a meaningful benefit have not been verified.
Required materials and conditions: Original handgrip treatment contrast, variance, CI, exact P, and analysis population/model
Materials to obtain first: Original handgrip treatment contrast, variance, CI, exact P, and analysis population/model
Further research: If the original between-group handgrip estimate/interval and analysis definition are acquired, compare them separately from clinical importance.
Remaining uncertainty: There is a statement of nonsignificance, but magnitude, precision, and exclusion of a meaningful benefit have not been verified.
Conditions for verification: Preserve the nonsignificant report together with unverified numerical values/intervals, and do not make new calculations.
Why this condition is needed: This is needed to avoid turning a statement about significance into a quantitative effect magnitude or exclusion of benefit.
Application exceptions: The statement that a quantitative contrast was not reported is limited to the retained extraction currently read.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01

N16 · Is funding from indirect trials being borrowed as independent efficacy replication?

Current findings: TF01 funding was from Canterbury Medical Research Foundation and Sanitarium Health Food Company; product provision was not reported. TF02 records Danish foundations, and TF03 records Russian foundation/State Task support; product provision is unverified. These were not borrowed to assign the independence axis for directly eligible evidence.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Funding is reported, but complete product/author conflict-of-interest information and eligible independent replication have not been verified.
Reason for missing information: Funding is reported, but complete product/author conflict-of-interest information and eligible independent replication have not been verified.
Required materials and conditions: TF01/TF02/TF03 funding, product provision, author declarations/patents, and family relationships
Materials to obtain first: TF01/TF02/TF03 funding, product provision, author declarations/patents, and family relationships
Further research: Compare original Funding/COI, product provision, and family relationships by outcome.
Remaining uncertainty: Funding is reported, but complete product/author conflict-of-interest information and eligible independent replication have not been verified.
Conditions for verification: Distinguish retained funding and not-reported/unverified provision information from the currently unscored independence axis.
Why this condition is needed: This is needed to avoid turning the names of public/private funders into absence of product provision or conflicts of interest, or into independent replication.
Application exceptions: Do not automatically exclude a study because funding exists or establish bias because it is unknown.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S04 S05

N17 · Is a handgrip excerpt from an IBD-fatigue crossover trial the target result?

Current findings: TARIF is a 40-participant trial in quiescent IBD with severe chronic fatigue, with fatigue as the primary endpoint. An objectively weak enrollment population or prespecified low-strength treatment stratum was not verified, and handgrip nonsignificance is in the context of an indexed excerpt. Existing fatigue verdict 3086 was not changed.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Related human research exists, but population eligibility and handgrip values/denominators have not been verified.
Reason for missing information: Related human research exists, but population eligibility and handgrip values/denominators have not been verified.
Required materials and conditions: TARIF baseline reduced-strength enrollment/strata, handgrip analysis results, and fatigue/handgrip hierarchy
Materials to obtain first: TARIF baseline reduced-strength enrollment/strata, handgrip analysis results, and fatigue/handgrip hierarchy
Further research: Compare original handgrip subgroups, results, and denominators with the prespecified plan to reassess eligibility.
Remaining uncertainty: Related human research exists, but population eligibility and handgrip values/denominators have not been verified.
Conditions for verification: Separate the existence of the 40-participant fatigue trial from gaps concerning the target population and quantitative handgrip results.
Why this condition is needed: This is needed to avoid turning severe chronic fatigue and a secondary handgrip excerpt into a direct effect in an objectively weak population.
Application exceptions: Do not modify existing fatigue verdict 3086 or borrow it to score handgrip efficacy.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S03 S04

N18 · Are the 40 participants across two periods being counted as independent participants or a between-group handgrip effect?

Current findings: The retained TARIF record describes a 40-participant crossover trial comparing 600–1800 mg/day in 4-week periods separated by a 4-week washout. Handgrip analysis denominators, quantitative effect/CI, paired data, and carryover handling were not verified. Participants were not combined as independent people/trials across the two periods.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The crossover schedule is available, but the target handgrip estimand, denominator, model, and precision are unverified.
Reason for missing information: The crossover schedule is available, but the target handgrip estimand, denominator, model, and precision are unverified.
Required materials and conditions: 4-week treatment, 4-week washout, sequence/period, paired data, handgrip analysis counts, and carryover/model
Materials to obtain first: 4-week treatment, 4-week washout, sequence/period, paired data, handgrip analysis counts, and carryover/model
Further research: Verify sequence, period, paired variance, handling of carryover, and actual denominators in the original crossover handgrip analysis.
Remaining uncertainty: The crossover schedule is available, but the target handgrip estimand, denominator, model, and precision are unverified.
Conditions for verification: Distinguish the retained schedule and nominal dose from unverified handgrip-specific analysis.
Why this condition is needed: This is needed to avoid summing crossover participants as new people in each period or borrowing fatigue analysis as handgrip analysis.
Application exceptions: Do not create an eligible crossover estimand while population/endpoint mismatches remain unresolved.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S03 S04

N19 · Have the NCT identifier and actual reading of the plan/amendment history been distinguished?

Current findings: NCT03634735 is an identifier verified in the original report. At that time, an official page shell, web API error, and native API DNS failure prevented verification of the content; prospective registration timing was also not independently verified. No new registration lookup was performed in this work.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The number is available, but comparison of the actual plan, handgrip hierarchy, amendments, and prospective timing is unverified.
Reason for missing information: The number is available, but comparison of the actual plan, handgrip hierarchy, amendments, and prospective timing is unverified.
Required materials and conditions: Structured content of NCT03634735, original registration timing, handgrip hierarchy/analysis, and amendment history
Materials to obtain first: Structured content of NCT03634735, original registration timing, handgrip hierarchy/analysis, and amendment history
Further research: In an authorized update, compare the official registration/history with the handgrip plan in the original report.
Remaining uncertainty: The number is available, but comparison of the actual plan, handgrip hierarchy, amendments, and prospective timing is unverified.
Conditions for verification: Preserve verification of the identifier and unverified content/history, without newly assigning a current Inaccessible status.
Why this condition is needed: This is needed to avoid turning a registration number into prospective registration or completion of selective-reporting assessment.
Application exceptions: Distinguish historical shell/API/DNS failures from external access not attempted in this work.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S18

N20 · Is the supplied 3086 extraction being read as new full-text reading or independent replication?

Current findings: S19 is a lead from the previously supplied 3086 snapshot concerning the TARIF metabolic analysis and PMID34592862 maintenance follow-up. It is a historical record reusing the same family and oral HCl identity context, not new original full-text reading, fatigue reassessment, or handgrip replication in this work.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: A supplied record exists, but report-specific handgrip results/eligibility and current comparison with original texts are unverified.
Reason for missing information: A supplied record exists, but report-specific handgrip results/eligibility and current comparison with original texts are unverified.
Required materials and conditions: Original identities of subsequent metabolic/maintenance reports, common family/population, and handgrip endpoint/access
Materials to obtain first: Original identities of subsequent metabolic/maintenance reports, common family/population, and handgrip endpoint/access
Further research: Verify the original identity, cohort, and handgrip data in each subsequent report, and link it to the same family.
Remaining uncertainty: A supplied record exists, but report-specific handgrip results/eligibility and current comparison with original texts are unverified.
Conditions for verification: Distinguish the historical supplied-material/multiple-report role of S19 from unverified handgrip results.
Why this condition is needed: This is needed to avoid counting the hydrochloride lead in previously supplied material and subsequent fatigue analyses as new handgrip trials.
Application exceptions: Do not record that older protected_input files or external subsequent full texts were opened in this work.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S19

N21 · Are the 15, 14, 5, and 2 participants counted as the same trial of a pure oral preparation in adults?

Current findings: The retained CMT supplementary material records 14 adults among 15 participants, 5 adult hydrochloride rows, and 2 participants identified in the long-term hydrochloride handgrip figure. A patient aged 16, derivatives, and other treatments are mixed in. These denominators were not used as a single randomized oral-treatment comparison in adults or as a total of independent participants.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The mixed composition is recorded, but there is no matched control or between-group handgrip estimate for a pure oral preparation in adults.
Reason for missing information: The mixed composition is recorded, but there is no matched control or between-group handgrip estimate for a pure oral preparation in adults.
Required materials and conditions: Age, formulation, other treatments, and participants/denominators for handgrip follow-up in each row of the CMT supplementary material
Materials to obtain first: Age, formulation, other treatments, and participants/denominators for handgrip follow-up in each row of the CMT supplementary material
Further research: Link age, formulation, and follow-up results from the original Table S1/figures to individual rows.
Remaining uncertainty: The mixed composition is recorded, but there is no matched control or between-group handgrip estimate for a pure oral preparation in adults.
Conditions for verification: Preserve the supplementary material's 15 participants/14 adults, 5 adult HCl rows, and 2 participants with long-term HCl handgrip observations according to their respective roles.
Why this condition is needed: Needed to avoid combining mixed formulations, a participant aged 16, other treatments, and different denominators into a single oral-treatment result in adults.
Application exceptions: The existing denominators are historical extractions; no additional totals or effect calculations are generated in this work.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S05 S06 S07

N22 · Were HCl in patients 1 and 3 distinguished from sulbutiamine in patient 2?

Current findings: In the retained Figure 1 description, patients 1 and 3 received thiamine HCl, and patient 2 received sulbutiamine. The Russian/English reports and supplementary material belong to the same family. Before-and-after handgrip observations were not converted into a causal between-group effect, and derivatives were not pooled with ordinary thiamine.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Patients/formulations were distinguished, but a matched comparator and quantitative between-group handgrip effect remain unverified.
Reason for missing information: Patients/formulations were distinguished, but a matched comparator and quantitative between-group handgrip effect remain unverified.
Required materials and conditions: Patient-specific formulations, durations, handgrip follow-up, concomitant treatments/controls, and original measurements in Figure 1
Materials to obtain first: Patient-specific formulations, durations, handgrip follow-up, concomitant treatments/controls, and original measurements in Figure 1
Further research: Compare each patient's handgrip follow-up with actual exposure/concomitant treatment, and obtain comparison data under the same conditions separately.
Remaining uncertainty: Patients/formulations were distinguished, but a matched comparator and quantitative between-group handgrip effect remain unverified.
Conditions for verification: Preserve individual formulations and uncontrolled follow-up without repurposing them as comparative efficacy evidence.
Why this condition is needed: Needed to avoid converting favorable before-and-after observations into a causal between-group effect of ordinary thiamine.
Application exceptions: The Russian/English reports concern the same cohort/translation and are not independent replications.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S05 S06 S07

N23 · Is a healthy-person biomarker comparison an untreated handgrip control?

Current findings: The currently retained record does not treat the healthy metabolic comparison group as an untreated long-term handgrip control. Figure S2 contains biomarker data, not a handgrip treatment contrast. The visual review of 3 supplementary PDF pages for S06 is a historical access record.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies the boundary preventing repurposing of other outcomes/controls. It does not establish acquisition of an eligible handgrip comparison.
Reason for missing information: This verifies the boundary preventing repurposing of other outcomes/controls. It does not establish acquisition of an eligible handgrip comparison.
Required materials and conditions: Actual comparators, tests, and time points for the biomarker comparison/Figure S2 and long-term handgrip observations
Materials to obtain first: Actual comparators, tests, and time points for the biomarker comparison/Figure S2 and long-term handgrip observations
Further research: Check the original materials for an actual control with the same handgrip measurement, time point, and exposure.
Remaining uncertainty: This verifies the boundary preventing repurposing of other outcomes/controls. It does not establish acquisition of an eligible handgrip comparison.
Conditions for verification: Record the comparative meaning of biomarkers and handgrip, and the unverified control, separately.
Why this condition is needed: Needed to avoid importing healthy controls for different outcomes/time points into the same handgrip efficacy comparison.
Application exceptions: Distinguish the historical record of visual review of 3 supplementary PDF pages from the current reading of the summary.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S05 S06

N24 · Were the existence of a correction and verification of its actual full text distinguished?

Current findings: S08 records the existence of a formal correction, but its full text was inaccessible at the time. Distinguish the original publisher's page-range correction of 1–22→1161–1182 from the search excerpt about gray shading in Table3. The excerpt was not promoted to verified correction text, and no new correction lookup was performed in this work.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The existence/bibliographic record of a correction and its actual impact on clinical text have different levels of verification.
Reason for missing information: The existence/bibliographic record of a correction and its actual impact on clinical text have different levels of verification.
Required materials and conditions: Original/corrected versions, page changes, scope of text/table corrections, and effects on attribution of handgrip observations
Materials to obtain first: Original/corrected versions, page changes, scope of text/table corrections, and effects on attribution of handgrip observations
Further research: During a permitted update, compare the complete correction with the original table and review linked observations/statuses.
Remaining uncertainty: The existence/bibliographic record of a correction and its actual impact on clinical text have different levels of verification.
Conditions for verification: Preserve the historical correction notice, page correction, unacquired full text, and excerpt limitations.
Why this condition is needed: Needed to avoid treating a bibliographic correction, inaccessible full text, or search excerpt as a fully verified clinical correction.
Application exceptions: Do not count a correction within the same family as a new trial or use the gray-shading excerpt as a verified fact.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S08

N25 · Are the two DM1 cases being read as an oral-treatment handgrip comparison?

Current findings: The two DM1 cases in S09 involved intramuscular thiamine 100 mg 2 times per week, not a controlled oral-treatment dynamometer trial. The historical full_text_HTML access record was not reused as a claim of current full-text reading.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This is a retained classification verifying differences in route/design, not verification of target efficacy.
Reason for missing information: This is a retained classification verifying differences in route/design, not verification of target efficacy.
Required materials and conditions: Actual route, 100 mg 2 times per week, symptoms/measurements, and presence or absence of a control in the DM1 cases
Materials to obtain first: Actual route, 100 mg 2 times per week, symptoms/measurements, and presence or absence of a control in the DM1 cases
Further research: Preserve the exposures/measurements in the original cases and review the target oral-treatment handgrip comparison using separate materials.
Remaining uncertainty: This is a retained classification verifying differences in route/design, not verification of target efficacy.
Conditions for verification: Indicate the 2 cases, injection route, uncontrolled design, and current non-reading of the external full text.
Why this condition is needed: Needed to avoid transferring uncontrolled improvement with intramuscular injections to an effect of single-ingredient oral treatment on handgrip.
Application exceptions: Preserve the existence of the cases rather than recasting it as an absence of human research; distinguish only their eligibility for the target question.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S09

N26 · Is well-being in healthy older women being transferred to a handgrip effect in people with low muscle strength?

Current findings: The retained S10 record concerns 80 healthy older women, 10 mg/day, and 6 weeks of double-blind treatment following a 4-week baseline. Selection for low muscle strength and a separate objective muscle-strength contrast were not verified, and well-being results were not borrowed as a handgrip benefit.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: An adjacent trial exists, but the target low-strength population/handgrip outcome remains unverified.
Reason for missing information: An adjacent trial exists, but the target low-strength population/handgrip outcome remains unverified.
Required materials and conditions: Smidt's baseline definition of low muscle strength, handgrip results, health/well-being endpoints, and denominators
Materials to obtain first: Smidt's baseline definition of low muscle strength, handgrip results, health/well-being endpoints, and denominators
Further research: If original eligibility criteria/handgrip measurements are available, compare them with the conditions of the same question.
Remaining uncertainty: An adjacent trial exists, but the target low-strength population/handgrip outcome remains unverified.
Conditions for verification: Distinguish the context of 80 participants/10 mg/6 weeks and a 4-week baseline from gaps in the target population/endpoint.
Why this condition is needed: Needed to avoid treating older age, marginal thiamine status, and improved well-being as the same handgrip outcome in objectively weak participants.
Application exceptions: Preserve the existence of the original trial in healthy participants without newly importing an effect size.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S10

N27 · Are the TTFD title and landing page being read as numerical evidence for ordinary thiamine?

Current findings: S11 identifies a different molecule from the title/landing page of an original TTFD article. The full text was not extracted, and no numerical results are claimed. It was not pooled as direct evidence for the ordinary-thiamine question.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies the molecular/access boundary, not original effect estimates or target efficacy.
Reason for missing information: This verifies the molecular/access boundary, not original effect estimates or target efficacy.
Required materials and conditions: Original molecular identity, title/material type, and level of access to actual population/measurement results
Materials to obtain first: Original molecular identity, title/material type, and level of access to actual population/measurement results
Further research: Link the derivative to a separate question and verify direct results for ordinary thiamine separately.
Remaining uncertainty: This verifies the molecular/access boundary, not original effect estimates or target efficacy.
Conditions for verification: Preserve both the molecular exclusion of TTFD and the lack of extraction of original numerical results.
Why this condition is needed: Needed to avoid pooling a derivative and an original article verified only at title level with handgrip effects of ordinary thiamine.
Application exceptions: Do not turn 'double blind' in a title into a complete extraction of methods/numbers.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S11

N28 · Is an isokinetic P>0.05 in healthy participants being read as no handgrip effect?

Current findings: Doyle concerns a placebo crossover study of allithiamine 1 g/day for 5 days in 15 healthy students, with isokinetic muscle performance measured using Biodex System2. P>0.05 does not establish no effect or equivalence for ordinary thiamine, adults with low muscle strength, and handgrip.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies the boundary for a different molecule/population/endpoint. The target effect size/interval remains unverified.
Reason for missing information: This verifies the boundary for a different molecule/population/endpoint. The target effect size/interval remains unverified.
Required materials and conditions: Allithiamine, 15 healthy students, 5 days/1 g, Biodex isokinetic results, and original intervals
Materials to obtain first: Allithiamine, 15 healthy students, 5 days/1 g, Biodex isokinetic results, and original intervals
Further research: Attribute the original result to its derivative/isokinetic question and review the handgrip comparison separately.
Remaining uncertainty: This verifies the boundary for a different molecule/population/endpoint. The target effect size/interval remains unverified.
Conditions for verification: Indicate differences in molecule/population/endpoint together with the limitations of nonsignificance.
Why this condition is needed: Needed to avoid converting nonsignificance for a derivative, a different population, and a different muscle-strength endpoint into a target effect of 0.
Application exceptions: The existing P>0.05 is a historical report; no exact P value or equivalence interval is generated.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S12

N29 · Were FIM recovery, actual handgrip, and an oral-treatment comparison distinguished?

Current findings: S13 contains FIM functional-limitation/recovery data. Detailed methods and route/comparator could not be verified from the historical indexed abstract excerpt and full-text 402 failure record. FIM was not converted into a separate handgrip contrast.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Adjacent functional data exist, but the identity of the target oral treatment/handgrip outcome/comparator remains unverified.
Reason for missing information: Adjacent functional data exist, but the identity of the target oral treatment/handgrip outcome/comparator remains unverified.
Required materials and conditions: FIM results, actual route/comparator, separate handgrip testing, and access to original methods
Materials to obtain first: FIM results, actual route/comparator, separate handgrip testing, and access to original methods
Further research: If original methods/handgrip data are acquired, compare the actual route, control, and endpoint for correspondence.
Remaining uncertainty: Adjacent functional data exist, but the identity of the target oral treatment/handgrip outcome/comparator remains unverified.
Conditions for verification: Retain the general functional endpoint and unverified route/methods.
Why this condition is needed: Needed to avoid transferring overall function in deficiency neuropathy to an isolated handgrip outcome.
Application exceptions: Do not infer an oral preparation/comparator from inaccessible methods.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S13

N30 · Do PBC fatigue and B-vitamin/magnesium results replicate a single-ingredient handgrip effect?

Current findings: S20 is a PBC fatigue trial and is not counted as a refutation or replication for handgrip. S21 is a lead for an IBD fatigue trial of combined B1/B6/B12+magnesium, from which the handgrip efficacy of B1 alone cannot be isolated. The unverified DOI in the 2026 record and the status of the supplied composition snapshot were preserved.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies the boundary for another disease, a combination, and fatigue. It does not establish acquisition of a target handgrip comparison.
Reason for missing information: This verifies the boundary for another disease, a combination, and fatigue. It does not establish acquisition of a target handgrip comparison.
Required materials and conditions: The disease/endpoint in S20 and the combined ingredients/fatigue question and original access in S21
Materials to obtain first: The disease/endpoint in S20 and the combined ingredients/fatigue question and original access in S21
Further research: Separate actual results by question and review the single-ingredient handgrip comparison using separate materials.
Remaining uncertainty: This verifies the boundary for another disease, a combination, and fatigue. It does not establish acquisition of a target handgrip comparison.
Conditions for verification: Preserve differences in disease/endpoint/ingredient eligibility for each source.
Why this condition is needed: Needed to avoid attributing results for fatigue in another disease or for a combined intervention to ordinary thiamine alone for handgrip.
Application exceptions: Do not borrow effect sizes or rescore the existing fatigue assessment.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S20 S21

N31 · Is a micronutrient association in Korean adults being recast as supplementation efficacy?

Current findings: S23 contains dietary observational data on micronutrients and handgrip in Korean adults. It is not randomized assignment to single-ingredient oral supplementation; dietary intake was not converted into a supplementation dose, and the association was not converted into causal efficacy.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies the association/intervention boundary, not direct handgrip efficacy or a need for supplementation.
Reason for missing information: This verifies the association/intervention boundary, not direct handgrip efficacy or a need for supplementation.
Required materials and conditions: Dietary observational design, direction of the exposure/handgrip association, and presence or absence of an actual randomized supplementation comparison
Materials to obtain first: Dietary observational design, direction of the exposure/handgrip association, and presence or absence of an actual randomized supplementation comparison
Further research: Link the dietary association to its original direction and verify a single-ingredient supplementation handgrip comparison separately.
Remaining uncertainty: This verifies the association/intervention boundary, not direct handgrip efficacy or a need for supplementation.
Conditions for verification: Indicate the difference between questions about observational associations and intervention comparisons.
Why this condition is needed: Needed to avoid converting a dietary-intake association into a single-ingredient treatment or a supplementation dose/need.
Application exceptions: Do not calculate a supplementation dose from dietary intake in this work or import the original observational effect.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S23

N32 · How should 23 sources, 11 families, and 0 directly eligible comparisons be interpreted?

Current findings: The 23 current sources/citations entries are a provenance list mixing clinical reports, supplements/corrections, registrations, safety sources, reviews, and bibliographic leads. The records of 11 structural families and 0 directly eligible comparisons are preserved without interpreting them as an absence of all human research. CMT translations/supplements/corrections and TARIF follow-up reports belong to their respective existing families; the TF01 related report from 2000 remains only an unverified lead for possibly shared recruitment of 222 people.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies the retained family/duplication policy. Total unique study/participant counts from a comprehensive search have not been verified.
Reason for missing information: This verifies the retained family/duplication policy. Total unique study/participant counts from a comprehensive search have not been verified.
Required materials and conditions: Links from report to study/case family to endpoint/time point; provisionally related reports; duplication/unique counts
Materials to obtain first: Links from report to study/case family to endpoint/time point; provisionally related reports; duplication/unique counts
Further research: Verify recruitment/registration/population/result links for each report and preserve relationships identified as the same or unknown.
Remaining uncertainty: This verifies the retained family/duplication policy. Total unique study/participant counts from a comprehensive search have not been verified.
Conditions for verification: Distinguish the current structural family/report relationships from unverified overall unique study/participant counts.
Why this condition is needed: Needed to avoid counting bibliographic records, registrations, safety sources, reviews, and access attempts as 23 trials, or converting 0 directly eligible comparisons into 0 human studies.
Application exceptions: Do not treat the TF01 lead for potentially shared recruitment of 222 people as a verified independent trial or an additional denominator.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S02 S03 S04 S05 S06 S07 S08 S18 S19 S22

N33 · Is an unverified effect being filled in using within-group changes or baseline handgrip?

Current findings: For eligible handgrip, primary_effect, primary_CI, and primary_p are null, and the effect direction is unknown. E0/E+ was not assigned from within-group changes, baseline handgrip, or adjacent nonsignificant findings, and no new clinical calculations were performed in this work.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The eligible effect of interest, original analysis population/model, and estimate/interval remain unverified.
Reason for missing information: The eligible effect of interest, original analysis population/model, and estimate/interval remain unverified.
Required materials and conditions: Eligible between-group handgrip estimand; ITT/PP/adjustment; original effect/CI/exact P; denominators
Materials to obtain first: Eligible between-group handgrip estimand; ITT/PP/adjustment; original effect/CI/exact P; denominators
Further research: Verify the effect of interest, population, and between-group estimate/interval together in an eligible original analysis.
Remaining uncertainty: The eligible effect of interest, original analysis population/model, and estimate/interval remain unverified.
Conditions for verification: Keep primary_effect/CI/P null and no_effect_claim=false.
Why this condition is needed: Needed to avoid constructing a target causal effect from baseline values, nonsignificance, or favorable before-and-after observations in adjacent studies.
Application exceptions: Do not fill invalid raw calculation suggestions or an eligibility-schema gap with an effect of 0.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S03 S05

N34 · Does objective handgrip guarantee a benefit in daily function or clinical events?

Current findings: An eligible between-group CI and MCID have not been verified. Objective measurement alone does not make handgrip H or P, and force measurement differs from improvement in daily function. The existing axes remain unscored; no arbitrary P/S, C1/C0/CX, or participant-count/duration criteria were assigned.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Without an effect interval, its importance, and the meaning of the actual measurement, a meaningful benefit can neither be established nor ruled out.
Reason for missing information: Without an effect interval, its importance, and the meaning of the actual measurement, a meaningful benefit can neither be established nor ruled out.
Required materials and conditions: Eligible handgrip interval, justified important difference, meaning of the test, and separate daily-function outcomes
Materials to obtain first: Eligible handgrip interval, justified important difference, meaning of the test, and separate daily-function outcomes
Further research: Verify the original interval and a valid criterion for handgrip importance; review function/events separately using direct data.
Remaining uncertainty: Without an effect interval, its importance, and the meaning of the actual measurement, a meaningful benefit can neither be established nor ruled out.
Conditions for verification: Distinguish unverified importance/intervals and test meaning from separate function/event questions.
Why this condition is needed: Needed to avoid arbitrarily establishing patient-important benefit, H/P, or equivalence from objectivity, significance, or sample size.
Application exceptions: Do not assign an unsupported MCID, required participant count/duration, or P/S as new numbers/axes.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources

N35 · Is selective reporting being established merely because an eligible registration/plan is unavailable?

Current findings: No directly eligible handgrip trial could be selected, so comparison with its registration/plan remains unverified. The unverified TF01 registration, the distinction between TF03 ethics approval and trial registration, and TARIF history-access limitations were preserved. These are not interpreted as confirmed selective reporting.
Verification status: Unverified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Materials needed to verify an eligible comparison of the prespecified plan with the report and the original reasons for changes remain unverified.
Reason for missing information: Materials needed to verify an eligible comparison of the prespecified plan with the report and the original reasons for changes remain unverified.
Required materials and conditions: Eligible original registration/protocol/analysis plan, endpoints/time points, reasons for changes, and corrected versions
Materials to obtain first: Eligible original registration/protocol/analysis plan, endpoints/time points, reasons for changes, and corrected versions
Further research: After comparing an actual eligible plan with the handgrip report, record the scope of changes/selection.
Remaining uncertainty: Materials needed to verify an eligible comparison of the prespecified plan with the report and the original reasons for changes remain unverified.
Conditions for verification: Indicate the actual eligible plan that could not be compared and access limitations for adjacent materials.
Why this condition is needed: Needed to avoid converting unacquired plans into confirmed non-registration, selective reporting, or absence of original results.
Application exceptions: Do not use unverified TF01/TF03 registrations or the TARIF identifier as verification of an eligible plan.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S05 S18

N36 · Does a separate 100 mg SmPC provide the safety denominator for the target exposure?

Current findings: S15 records nausea, vomiting, diarrhea, abdominal pain, and hypersensitivity with unknown frequency for a specific oral thiamine hydrochloride 100 mg product. Allergy to product excipients is also separate. Harm denominators/frequencies in a target eligible trial and doses safe for long-term use in renal/hepatic impairment remain unverified.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: A separate product provides harm context, but incidence and long-term safety for the target population/actual exposure have not been verified.
Reason for missing information: A separate product provides harm context, but incidence and long-term safety for the target population/actual exposure have not been verified.
Required materials and conditions: Product-specific adverse reactions/frequencies in S15; eligible actual exposure/duration and population; collection, discontinuations, and denominators
Materials to obtain first: Product-specific adverse reactions/frequencies in S15; eligible actual exposure/duration and population; collection, discontinuations, and denominators
Further research: Link adverse-event collection, group-specific denominators/durations, and discontinuations for an eligible exposure to the product identity.
Remaining uncertainty: A separate product provides harm context, but incidence and long-term safety for the target population/actual exposure have not been verified.
Conditions for verification: Distinguish product-specific reactions from unverified target frequencies/denominators and doses safe for long-term use.
Why this condition is needed: Needed to avoid transferring precautions for an authorized product to individual safety or incidence in the target handgrip trial.
Application exceptions: Preserve existing cautions without deleting the efficacy manuscript because of gaps in harm information.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S15

N37 · Are injection-related hypersensitivity and product-specific pregnancy/pediatric restrictions being generalized?

Current findings: Reports of severe hypersensitivity were mainly observed with injections, and their risk rate is not applied to oral preparations. The S15 product is not intended for pregnancy/lactation and is not recommended below 3 years of age, but these restrictions are not generalized to contraindications to all nutritional thiamine intake. The adult handgrip question is not extended to children/pregnancy.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Route/product-specific cautions exist, but these materials do not verify population-specific safety in the target trial.
Reason for missing information: Route/product-specific cautions exist, but these materials do not verify population-specific safety in the target trial.
Required materials and conditions: Route of hypersensitivity reactions, product-specific pregnancy/lactation and age recommendations, and applicability to populations
Materials to obtain first: Route of hypersensitivity reactions, product-specific pregnancy/lactation and age recommendations, and applicability to populations
Further research: Link safety materials for the relevant product/route/population separately from the efficacy question.
Remaining uncertainty: Route/product-specific cautions exist, but these materials do not verify population-specific safety in the target trial.
Conditions for verification: Indicate historical cautions limited to the route/product/population without claiming established safety.
Why this condition is needed: Needed to avoid turning an injection-related anaphylaxis risk rate or product restrictions into contraindications to all oral nutritional intake.
Application exceptions: Do not extend the adult handgrip question to children or pregnancy.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S15

N38 · Do dialysis, malabsorption, and refeeding management establish the benefit of general handgrip supplementation?

Current findings: Furosemide may affect thiamine status, and fluorouracil requires separate review. Requirements in dialysis/malabsorption and medical management of alcohol-related deficiency/refeeding do not establish general high-dose oral handgrip efficacy or a safety upper limit. Combined NICE management is not used as evidence for single-ingredient efficacy.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Medical/drug caution contexts exist, but direct efficacy, the full range of interactions, and safety limits for the target exposure remain unverified.
Reason for missing information: Medical/drug caution contexts exist, but direct efficacy, the full range of interactions, and safety limits for the target exposure remain unverified.
Required materials and conditions: Drug interactions, requirements in dialysis/malabsorption, and actual medical management of alcohol-related deficiency/refeeding
Materials to obtain first: Drug interactions, requirements in dialysis/malabsorption, and actual medical management of alcohol-related deficiency/refeeding
Further research: Review relevant drugs/medical situations by product/population, separately from direct target handgrip data.
Remaining uncertainty: Medical/drug caution contexts exist, but direct efficacy, the full range of interactions, and safety limits for the target exposure remain unverified.
Conditions for verification: Distinguish the original medical/drug context from separate gaps in efficacy/safety.
Why this condition is needed: Needed to avoid converting different requirements or combined medical management into high-dose oral handgrip efficacy or a safety upper limit.
Application exceptions: Do not assert an absence of interactions or interpret this as an instruction to stop necessary deficiency treatment.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S14 S16 S17

N39 · Are the absence of an established UL and water solubility being read as unlimited safety?

Current findings: Retained S16 and safety_detail state that no UL was established because toxicity data were insufficient. Water solubility and urinary excretion do not guarantee unlimited safety. The target dose safe for long-term use in renal/hepatic impairment also remains unverified, and study doses are not individual recommendations.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: The reason for the absence of a UL is recorded, but this does not verify target high-dose/long-term safety.
Reason for missing information: The reason for the absence of a UL is recorded, but this does not verify target high-dose/long-term safety.
Required materials and conditions: Reason no UL was established, actual toxicity data, safety by population/dose/duration, and harm denominators
Materials to obtain first: Reason no UL was established, actual toxicity data, safety by population/dose/duration, and harm denominators
Further research: If toxicity/harm data for a population/exposure are added, compare them with the original product and denominator/duration.
Remaining uncertainty: The reason for the absence of a UL is recorded, but this does not verify target high-dose/long-term safety.
Conditions for verification: Record both the reason no limit was established and the unverified therapeutic dose/long-term safety.
Why this condition is needed: Needed to avoid turning insufficient data, water solubility, or excretion into a guarantee of high-dose safety for an individual.
Application exceptions: Do not propose unsupported numerical safety limits or doses.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S14 S16

N40 · Are data on optimal dose, maintenance, subgroups, and falls/mortality being imposed as mandatory for this table?

Current findings: The current standalone question concerns comparative handgrip efficacy, not optimal dose, persistence after discontinuation, or prevention of falls/mortality. Extension studies are not imposed as requirements for this narrow question. Unverified actual target dose, duration/principal time point, and direct handgrip effect remain recorded in earlier rows.
Verification status: Not applicable
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: Requiring expanded questions is not applicable. This does not replace gaps in the original handgrip exposure/population/outcome or verify effects for expanded questions.
Reason for missing information: Requiring expanded questions is not applicable. This does not replace gaps in the original handgrip exposure/population/outcome or verify effects for expanded questions.
Required materials and conditions: Identity and direct evidence for the original handgrip question and separate dose, maintenance, function, and event extensions
Materials to obtain first: Identity and direct evidence for the original handgrip question and separate dose, maintenance, function, and event extensions
Further research: If an expanded question is raised separately, review direct dose, follow-up, subgroup, function, and event results separately.
Remaining uncertainty: Requiring expanded questions is not applicable. This does not replace gaps in the original handgrip exposure/population/outcome or verify effects for expanded questions.
Conditions for verification: Do not impose the extensions themselves as requirements for the current question; distinguish them from actual exposure/denominator gaps.
Why this condition is needed: Needed to avoid requiring every extension study for a narrow, unresolved handgrip question or expanding an adjacent main effect.
Application exceptions: Do not turn unverified exposure/duration essential to the original comparative handgrip question into NA.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources

N41 · Is unverified eligibility in the recorded search being declared an absence of human research?

Current findings: The original evidence cutoff date is 2026-09-16, and the original reader-facing answer limits its statement to no directly eligible controlled result being verified in the recorded search. The S22 review serves only as a literature map/indexed excerpt and is not used for decisive numbers or scoring. No new search, correction/retraction lookup, or reading of old search/extraction files was performed in this work.
Verification status: Partly verified
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: A retained search scope exists, but an up-to-date exhaustive/unpublished-study/correction check and actual comparison with old separate files were not performed.
Reason for missing information: A retained search scope exists, but an up-to-date exhaustive/unpublished-study/correction check and actual comparison with old separate files were not performed.
Required materials and conditions: The 2026-09-16 search/cutoff date, actual inputs/failures, and scope for unpublished studies, registrations, corrections, and retractions
Materials to obtain first: The 2026-09-16 search/cutoff date, actual inputs/failures, and scope for unpublished studies, registrations, corrections, and retractions
Further research: In a separately permitted update, record actual search/registration/correction results and the scope of failures/unverified information.
Remaining uncertainty: A retained search scope exists, but an up-to-date exhaustive/unpublished-study/correction check and actual comparison with old separate files were not performed.
Conditions for verification: Distinguish the scope of the historical search/literature map and current local reading from incomplete external verification.
Why this condition is needed: Needed to avoid overstating the scope of an old search and the current table conversion as an up-to-date comprehensive search.
Application exceptions: Do not label the absence of external searching in this work or unacquired full texts as 0 studies or no recent corrections.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S22

N42 · Are the original ?/null, document A, and calculator exception being read as new evidence?

Current findings: The original grade is ?, the score is null, the safety label is Caution, and the downstream evidence axes remain unscored. Preserve human_study_exists=true alongside unverified direct eligibility. The calculator's eligibility gap/invalid raw suggestion is an unadopted historical record; the calculator was not run in this work. Document A/ChatGPT self-review is not independent clinical review or efficacy certification.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies the distinction between the roles of original values and document/calculation metadata. It is not a new clinical judgment or score.
Reason for missing information: This verifies the distinction between the roles of original values and document/calculation metadata. It is not a new clinical judgment or score.
Required materials and conditions: Original grade/score, unscored axes, eligibility exception, document evaluation, and reviewer identity
Materials to obtain first: Original grade/score, unscored axes, eligibility exception, document evaluation, and reviewer identity
Further research: Link new direct evidence or a schema change to a separate event/version and judgment.
Remaining uncertainty: This verifies the distinction between the roles of original values and document/calculation metadata. It is not a new clinical judgment or score.
Conditions for verification: Preserve the original ?/null/Caution, document A/self-review, and human_study_exists=true.
Why this condition is needed: Needed to avoid changing the original current values into a score of 0, no effect, no human research, or independent clinical certification.
Application exceptions: The invalid raw suggestion and calculator-schema problem are historical records, not a calculator run/reassessment in this work.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources

N43 · Are summary reading and historical full-text access being shown as the same verification?

Current findings: What was read in this work was the KO/evidence/bibliography/historical-access content of the retained summaries. Distinguish historical records of the reproduced HTML for S01, supplementary PDF for S06, full text for S09, and official safety full texts from the current non-reading of all external materials. snapshot_policy covers limited extraction/bibliography, not redistributed copies of original full texts. Link summary reading through exact locations/values and retained-summary SHAs.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies exact retained-summary linkage. It is not current clinical full-text reading or verification of external original bytes.
Reason for missing information: This verifies exact retained-summary linkage. It is not current clinical full-text reading or verification of external original bytes.
Required materials and conditions: Physical type, historical access level/location, current non-reading, and retained-summary pointer/literal/SHA for each material
Materials to obtain first: Physical type, historical access level/location, current non-reading, and retained-summary pointer/literal/SHA for each material
Further research: If new materials are permitted, link actual acquisition/reading and original bytes/versions to the relevant rows/materials.
Remaining uncertainty: This verifies exact retained-summary linkage. It is not current clinical full-text reading or verification of external original bytes.
Conditions for verification: Link summaries to exact retained locations and indicate current non-attempted/non-read external access and the absence of preserved original bytes.
Why this condition is needed: Needed to avoid turning local-summary reading or historical 3rd-party full-text/abstract access or registration-access failures into current reading of original clinical sources.
Application exceptions: The stored-manuscript SHA is not a hash of the original bytes of an external PDF/original article.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources S01 S06 S09 S14 S15 S16 S18 S19

N44 · Is historical deployment metadata being read as publication in this work?

Current findings: Preserve current ID3117, the original URL, the 2026-09-16 cutoff/publication date, historical server_deployed metadata, and revision_history. The review date of the retained sheet is 2026-10-05, and no public deployment was performed in that review. New eligible comparisons, original methods/strata, plans, or corrections/errors trigger separate review of rows/conditions/materials.
Verification status: Met
Materials actually read: Only the designated retained summaries were actually read. External original texts and older separate files remain unread in this work.
Why unverified: This verifies preservation of identity/date/update links. It is not publication in this work or verification of the latest corrections.
Reason for missing information: This verifies preservation of identity/date/update links. It is not publication in this work or verification of the latest corrections.
Required materials and conditions: Current ID/URL, evidence/review dates, original revision/deployment metadata, and links between update events/criteria versions
Materials to obtain first: Current ID/URL, evidence/review dates, original revision/deployment metadata, and links between update events/criteria versions
Further research: If new materials/corrections are permitted, preserve the full original text and review it with links to events, versions, and change decisions.
Remaining uncertainty: This verifies preservation of identity/date/update links. It is not publication in this work or verification of the latest corrections.
Conditions for verification: Distinguish current identity/original dates from this review/unpublished status and establish update rules for linked rows.
Why this condition is needed: Needed to avoid presenting historical site deployment and current local-sheet creation as the same completion.
Application exceptions: Preserve original materials, unfavorable results, unverified information, and assessments; record changed conditions and new evidence separately.
Referenced methods: Internal case-specific adaptation of the retained M03/M04/M08/M15/M19 principles on questions, families, measurement/analysis/uncertainty, and harms. This is not formal application of a methodology or clinical certification.

Related sources